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ABSTRACT

Currently, over one-third of the global population is infected with tuberculosis (TB), one
of the world’s most deadly infectious diseases. The current vaccine against TB, Bacille
Calmette-Guérin (BCG), is a live attenuated vaccine that is intradermally administered in
over 150 countries around the world. Despite its widespread use, the vaccine has a variable
protective efficacy of 0-80%, with the lowest efficacy rates in regions of the world where
TB is most prevalent. This variability is partially due to environmental mycobacteria (EM)
found in soil and water sources in areas of the world where BCG efficacy is poor.
The research hypothesis of this work is that pulmonary BCG vaccination in EMexposed hosts will be protective against TB. To test our hypothesis, we divided our
research into three aims. In Chapter 2, we will focus on the first two research aims of this
work which show: 1) Oral tolerance to EM is responsible for BCG protective variability,
and 2) Pulmonary immunization is necessary for protective efficacy in individuals exposed
to EM. To determine if the route of EM exposure played a role in immunosuppression
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against BCG, we exposed mice chronically, by either the oral or intradermal (ID) route, to
Mycobacterium avium, a specific species of EM. Here we show the role of EM exposure
route in the suppression of the murine immune response to BCG using flow cytometry and
ELISA methodologies to determine a tolerant immunophenotype. This data suggests oral
tolerance as a plausible mechanism for EM interference with ID BCG vaccination. Lastly,
we use pulmonary immunization to generate a robust immune response to BCG in the lung
airway, where EM immunity has not been generated. We again exposed mice chronically
to M. avium by the oral route to mimic human exposure. Next, mice were vaccinated either
by the ID route with BCG Pasteur to mimic the current BCG vaccination regimen or by the
pulmonary route. We demonstrate that pulmonary BCG immunization is protective in EMexposed mice later challenged with TB. Our data indicate that mucosal vaccination against
TB by the pulmonary route may increase BCG vaccine efficacy by avoiding the
immunosuppressive inference generated by chronic exposure to EM.
In Chapter 3, we describe our third research aim, which shows that factorial design
of excipients created a temperature-stable dry powder BCG that was suitable for pulmonary
administration. First, dry powder formulations were assessed for storage temperature and
moisture stability using a factorial design of excipients. Three optimal dry powder
formulations were selected based on stability and flow characteristics, and these powders
were spray-dried with live BCG to yield dry powders with a size in the range of 1-5 µm.
BCG dry powders have been and will continue to be assessed for viability and shelf-life.
This spray-dried live BCG is predicted to be highly stable and antigenic, providing the
ideal inhalable vaccine delivery platform for EM-exposed mouse vaccination.

vi

TABLE OF CONTENTS
DEDICATION ............................................................................................................... iii
ACKNOWLEDGMENTS .............................................................................................. iv
ABSTRACT .................................................................................................................... v
TABLE OF CONTENTS .............................................................................................. vii
LIST OF FIGURES......................................................................................................... x
LIST OF TABLES ........................................................................................................ xii
Chapter 1.

INTRODUCTION ........................................................................................ 1

Mycobacterial Biology .................................................................................................... 2
TB Immunology .............................................................................................................. 6
Early events of infection .............................................................................................. 6
Delayed adaptive immunity ......................................................................................... 7
Humoral immunity and innate lymphocytes ............................................................... 9
Latent infection .......................................................................................................... 10
Correlates of protection and tolerance ....................................................................... 12
Treatment of Mtb .......................................................................................................... 14
The rise of antibiotic resistant Mtb ............................................................................ 15
Bacille Calmette-Guérin (BCG) vaccine....................................................................... 18
History of BCG delivery............................................................................................ 18
Failures of BCG ......................................................................................................... 19
Other vaccine platforms ................................................................................................ 25
Live bacterial vaccines .............................................................................................. 25
Inactivated whole-cell vaccines ................................................................................. 27
Viral vector-based TB vaccines ................................................................................. 27
Heterologous prime-boost vaccination strategies in TB............................................ 29
Pulmonary immunization .............................................................................................. 31
Biomimicry: harnessing natural immunity for protection against TB ....................... 31
Pulmonary immunization for global protection......................................................... 32
Safety concerns for pulmonary immunization........................................................... 34
Role of adjuvants ....................................................................................................... 34
Live versus dead vaccines ......................................................................................... 35
vii

Dry powder vaccines ..................................................................................................... 37
Spray drying .............................................................................................................. 38
Excipient selection ..................................................................................................... 41
Thermostability.......................................................................................................... 41
Chapter 2. Oral tolerance to environmental mycobacteria interferes with intradermal,
but not pulmonary, immunization against tuberculosis .................................................... 44
Abstract ......................................................................................................................... 45
Author summary ............................................................................................................ 46
Introduction ................................................................................................................... 46
Results ........................................................................................................................... 49
Murine T cells are cross-specific to EM and BCG .................................................... 49
Increased tolerogenic immune profiles associated with oral EM exposure .............. 51
Mycobacterial colonization is dependent on route of exposure ................................ 53
Pulmonary versus intradermal BCG immunity ......................................................... 54
Pulmonary BCG vaccination increases correlates of protection in the airway of EMexposed mice ............................................................................................................. 55
Pulmonary BCG vaccination protects EM-exposed mice against Mtb ..................... 57
Discussion ..................................................................................................................... 60
Methods ......................................................................................................................... 65
Animals...................................................................................................................... 65
Mycobacteria ............................................................................................................. 65
Sensitization with EM ............................................................................................... 66
Vaccination ................................................................................................................ 66
Aerosol TB infection ................................................................................................. 67
Tissue preparation...................................................................................................... 67
Splenic lymphocytes .................................................................................................. 67
Lung tissue................................................................................................................. 67
Immunophenotyping via flow cytometry .................................................................. 68
T-cell restimulation and ELISA ................................................................................ 68
Histopathology........................................................................................................... 69
Statistical methods ..................................................................................................... 69
Acknowledgements ....................................................................................................... 70
Supplemental figures ..................................................................................................... 71
viii

Chapter 3.

Design and optimization of a temperature-stable dry powder BCG vaccine
72

Abstract ......................................................................................................................... 73
Introduction ................................................................................................................... 73
Results ........................................................................................................................... 75
Factorial design of excipients .................................................................................... 75
Optimized BCG dry powder characterization ........................................................... 79
Stability of BCG dry powders ................................................................................... 83
Discussion ..................................................................................................................... 85
Materials & Methods ..................................................................................................... 88
Factorial design of excipients .................................................................................... 88
Solution preparation .................................................................................................. 88
Culturing BCG........................................................................................................... 89
Spray drying .............................................................................................................. 89
Dry powder characterization ..................................................................................... 90
Storage stability studies ............................................................................................. 92
Acknowledgements ....................................................................................................... 93
Chapter 4.

SUMMARY AND DISCUSSION.............................................................. 94

Suitability of pulmonary immunization in EM exposed hosts ...................................... 95
Alternative strategies to investigating EM exposure and pulmonary BCG vaccination98
Future studies to optimize a dry powder BCG ............................................................ 100
Clinical implications of pulmonary BCG vaccination ................................................ 102
Appendix A: Abbreviations ............................................................................................ 106
Appendix B: References ................................................................................................. 109
Appendix C: Figures ....................................................................................................... 128
Appendix D: Tables ........................................................................................................ 150

ix

LIST OF FIGURES
Figure 1.1 The race between antibiotic development and evolution of Mtb drug
resistance. ................................................................................................................... 16
Figure 1.2 The global efficacy of BCG. ........................................................................... 20
Figure 1.3 Proposed mechanisms for BCG failure due to EM interference.. ................... 22
Figure 1.4 Biomimickry: Using natural Mtb infection to inform vaccine design.. .......... 31
Figure 1.5 The effect of immunization route on immunity in the airway......................... 33
Figure 1.6 The spray drying process. ................................................................................ 38
Figure 2.1 Differences in cytokine response to BCG immunization were observed
between mice that were or were not presensitized to oral M. avium prior to
intradermal BCG vaccination ..................................................................................... 50
Figure 2.2 Analysis of cell phenotypes present in spleen and lung tissues after oral or
intradermal presensitization to M. avium ................................................................... 52
Figure 2.3 Pulmonary versus intradermal BCG immunization ........................................ 54
Figure 2.4 Analysis of cellular correlates of protection in different immunization groups
with and without oral M. avium presensitization ....................................................... 56
Figure 2.5 Mtb aerosol challenge studies ......................................................................... 57
Figure 2.6 Histopathological analysis of lung and spleen tissue after Mtb aerosol
challenge in different immunization groups, with and without oral M. avium
presensitization ........................................................................................................... 59
Figure 2.7 Pulmonary BCG immunization is effective at protecting against Mtb in EMexposed hosts chronic oral exposure to EM generates systemic tolerance against
mycobacteria .............................................................................................................. 63
x

Figure 3.1 Effect of changing excipient ratios on powder physical properties ................ 76
Figure 3.2. Overall interaction of excipients and responses ............................................. 77
Figure 3.3 XRD crystallography graphs of optimized formulations ................................ 80
Figure 3.4 SEM and TEM visualizations of dry powder particles ................................... 82
Figure 3.5 BCG loss after spray drying ............................................................................ 83
Figure 3.6 Stability of package protected dry powders .................................................... 84
Figure 3.7 Stability of unprotected dry powders .............................................................. 85

LIST OF SUPPLEMENTAL FIGURES
Supplemental 2.1 M. avium CFUs in lung and spleen after different routes of
presensitization ........................................................................................................... 71
Supplemental 2.2 Animal weights after infection............................................................. 71

xi

LIST OF TABLES
Table 1.1 Different species of Mycobacteria ...................................................................... 5
Table 1.2 Antibiotics for treatment of TB ........................................................................ 17
Table 1.3 Different vaccines against TB in pre-clinical trials .......................................... 36
Table 1.4 Advantages and disadvantages of lyophilization and spray drying of vaccine
formulations ............................................................................................................... 37
Table 1.5 Effect of spray drying process parameters on dry powder characteristics ....... 40
Table 3.1 Optimal excipient mixtures ............................................................................... 78
Table 3.2 Yields and sizes of optimized formulations ...................................................... 79
Table 3.3 Residual moisture and moisture uptake. ........................................................... 81
Table 3.4 Properties of excipients used for spray-drying live BCG vaccine. ................... 89
Table 3.5 Storage conditions for powders. ....................................................................... 93

xii

Chapter 1.

T

INTRODUCTION

uberculosis (TB) has been known by many names. Ancient Hindu texts
termed the disease Rogaraj, meaning “king of all diseases”, and

Rajayakshma, meaning “disease of kings”1. The Greek physician Hippocrates (460-370
BC) called tuberculosis Phthisis, derived from phthinein, meaning “to waste away”, and
described it as the most prominent disease of the time, a disease which almost always ended
in death2. Shortly thereafter, the disease was known as Consumption because of its ability
to consume its victims. During the 19th century, names became even more poetically grim
as illness continued to spread worldwide; including the White Plague or the White Death,
Captain of All These Men of Death, Graveyard Cough, and the King’s Evil3.
Mention in historical texts, representation in art and artifacts, and pathology on
ancient human remains have prompted many scientists to propose that TB is the oldest and
most formidable pathogen mankind has ever faced. Tubercular DNA has been recovered
from the mummies of ancient Egypt and signs of tubercular decay have been observed on
500,000 year old Homo erectus skeletal remains found in Turkey4,5. While the precise time
of TB’s origin remains unknown, history tells us that TB has always plagued humanity,
and it has done so without prejudice both geographically and economically.
It wasn’t until 1882, when German microbiologist Robert Koch discovered the
tubercle bacillus, that an infectious bacteria was declared the causative agent of these
diseases of old6. After Koch’s discovery, a vaccine and different antibiotic treatments
against the bacteria followed. Tuberculosis, like smallpox, was presumed to be on the path
of eradication7. However, the onset of the Human Immunodeficiency Virus (HIV) scare in
1

the 1980s, along with the rise of drug resistance to first-line tuberculosis drugs, shattered
any hopes of worldwide TB elimination. In 1993, the World Health Organization (WHO)
declared TB a global emergency, calling the disease humanity’s greatest killer8.
Over two decades later, TB is still a global epidemic. The WHO estimates that over
a third of the world has the disease. Yearly disease incidence is up to 9 million people with
active TB, leading to a mortality rate of 1.5 million people every year9. These dismal
statistics rank TB as the second leading cause of death due to a single infectious agent, just
behind HIV9. However, this statistic is complicated by the fact that TB is also the primary
killer of HIV patients, with one in every three HIV patient deaths caused by TB9.
More recently, research efforts in the TB field have shifted from commonly used
therapeutics (such as antibiotics, chemotherapy, and radiation) to different
immunotherapies, drug re-purposing, and vaccines10–12. In this work, we will discuss two
strategies to immunize individuals against TB in areas of the world where the current
vaccine fails. This first chapter will review the appropriate microbiology, immunology,
and methodology as an introduction to the aforementioned research.

Mycobacterial Biology
Mycobacterium tuberculosis (Mtb) is the etiological pathogen of TB. It is a rod-shaped
bacterium measuring on average 2-4µm in length and 0.2-0.5µm in width13. The bacterium
is difficult to classify by common microbiology terms because of its unique structural
characteristics. Mtb cannot truly be classified as Gram-positive or Gram-negative because
it has cell wall components which fit into both classifications.

Using DNA-based

molecular taxonomy, mycobacteria are considered Gram-positive, as most mycobacterial
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genes show significant similarity to other Gram-positive bacteria, such as those in the
Bacillus genus14. However, some of the cell wall components of mycobacteria make them
unique among other Gram-positive bacteria. Mtb has a thick peptidoglycan layer and lacks
a true outer membrane, consistent with Gram-positive bacteria. Nevertheless, it also
contains lipopolysaccharide, a pseudoperiplasm, and does not retain a Gram stain; these
are properties of Gram-negative bacteria14. Thus Mtb, and its mycobacterial counterparts,
is classified as an atypical, acid-fast bacteria because of the impenetrability of its cell wall
to classical stains and the requirement of heat and acid to visualize the bacteria with dyes.
The genus name Mycobacteria means fungus-like bacterium, so named for its mold
or fungus-like appearance when it grows on culture medium15. Upon the genus’s inclusion
in the 1896 Atlas of Bacteriology by Lehmann and Neumann16, Mtb and Mycobacterium
leprae were both included as species. Shortly thereafter in 1898, Smith divided Mtb into
human and bovine pathogens, and in 1946 Wells added a third variant, the vole bacillus1.
Currently, these three types of Mtb are now regarded as three separate species: M.
tuberculosis, M. bovis, and M. microti. All are considered part of the M. tuberculosis
complex, along with one other strain, M. africanum1 (Table 1.1).
The bacterium is an obligate aerobe and facultative parasite often residing in
macrophages. Scientists speculate that this is one of many characteristics that allow the
bacteria to evade the immune system. Another characteristic that is associated with
virulence is the slow doubling time of the bacteria, which can take 15-20 hours13. There
are some faster-growing species of mycobacteria, such as Mycobacterium smegmatis,
which have a doubling time of about 2-3 hours. However, these species are often these are
less pathogenic.

3

Another division of the mycobacteria genus is made up of mycobacteria that live in
the environment. This group has been described with different terminology in the past
including tuberculoid, non-tuberculous mycobacteria, mycobacteria other than tubercle,
and environmental mycobacteria (EM). For this work, we will use the latter to refer to this
species subset.
EM are classified into four different groups based on the Runyon classification1.
This system categorizes bacteria based on growth rate and yellow pigment production in
response to light. The yellow pigment is derived from carotenoid production and it has
been suggested that it may be associated with decreased UV-sensitivity and survival17.
Photochromogens are slow growing and produce pigment when exposed to light.
Scotochromogens are slow growing and produce pigment regardless of whether they are
exposed to light. Nonchromogens are slow growing and never produce pigment. The last
group consists of rapidly growing mycobacteria.
These species are usually saprophytes and are rarely pathogenic1. However, they
can occasionally cause opportunistic infection in immunocompromised human hosts. As
EM live ubiquitously in the environment (in soil, air, and water sources) of different
regions of the world, these species may occur as residents of the skin, gut, and upper
respiratory tract1,18,19. Thus, the presence of EM in a diseased host does not necessarily
imply that it is responsible for any observed pathology.
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Table 1.1 Different species of Mycobacteria
M. tuberculosis complex:
M. tuberculosis*

M. bovis (bovis &

M. bovis BCG

M. microti*

M. africanum*

M. canetti

M. pinnipedii

M. nonchromogenicum*

caprae)*
M. avium complex (MAC) other related species:
M. intracellulare*
M. lepremurium*
M. avium*

M. paratuberculosis*

Slow growing photochromogens:
M. kansasii*
M. asiaticum*

M. marinum*

M. simiae*

Slow growing scotochromogens :
M. gordonae*
M. scrofulaceum*

M. szulgai*

Slow growing non-chromogens
M. branderi
M. celatum

M. gastri*

M. haemophilum*

M. farcinogenes*

M. malmoense*

M. shimoidei

M. shinshuense

M. triviale*

M. terrae*

M. ulcerans*

M. xenopi*

Rapid growers:
M. aichense

M. agri

M. aurum*

M. austroafricanum

M. chelonae

M. chitae*

M. chubuense

M. diernhoferi

M. duvalii*

M. fallux

M. flavescens*

M. fortuitum

M. gadium*

M. gilvum*

M. komossense*

M. neoaurum*

M. obuense

M. parafortuitum*

M. phlei*

M. porcium

M. pulveris

M. rhodesiae

M. senegalense*

M. segmatis*

M. sphagni

M. thermoresistibile*

M. tokaiense

M. vaccae*

M. confluentis

M. interjectum

M. intermedium

Non- or poorly cultivatable species:
M. leprae*
M. genavense

M. sylvaticum

*Included in the original approved list of species by Skerman et al. in 1980
This table was modified from a graph in Tuberculosis Bacteriology by C.H. Collins et al.
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TB Immunology
Early events of infection
Mtb infection is predominantly acquired via the pulmonary route. An infected host with
high bacterial burden and ruptured lung lesions releases droplets containing bacilli into the
air (by coughing, sneezing, etc.)20,21. Breathing in as few as one of these small droplets is
enough to cause infection, with the infectious dose being < 10 bacteria20. Once the bacilli
have gained entry into the lung airway and parenchyma, the initial events of infection and
the interplay between Mtb and the host are complex. Mtb has developed a multitude of
mechanisms for exploiting the host immune response in order to further its own survival
and spread.
The first stage of infection is mediated almost entirely by the innate immune
system. The mycobacteria are engulfed by phagocytic immune cells, upon activation of
TLR-2, -9, and other pathogen recognition receptors (including C-type lectin receptors and
mannose receptors)21–24. Activated macrophages release interferon-γ (IFN-γ) which
initiates autophagy, wherein the macrophage phagosome (containing the bacterium) fuses
with the lysosome; this increases the acidity in the phagolysosomal compartment and
subsequent bacterial death24,25. In addition, activated macrophages can control infection
via apoptosis and efferocytosis (the phagocytosis of infected cells)24,26–29.
Phagocytic activity and initial inflammation lead to early granuloma formation.
Classically, granuloma formation was thought to “wall off” the pathogen in an effort to
diminish bacterial replication while the adaptive arm of the immune system gained
momentum. However, more recently, research has demonstrated a bacterial advantage in
early infection of phagocytic cells21,26–28,30,31. Alveolar macrophages, dendritic cells, and
6

neutrophils are reservoirs by which Mtb can hide from adaptive immune cells24,27,30. This
is illustrated by research showing that adoptive transfer of antigen-specific T cells during
early infection does little to decrease bacterial numbers24,32.
However, Mtb manipulates macrophage recruitment into the lung and delays
antigen presentation in the draining lymph nodes. Bacterial cell lipids limit antigen
recognition and activation of macrophages while promoting the recruitment of permissive
macrophages to further infection21,24,33. Mtb replicates in these macrophages, preventing
both fusion of the phagosome and lysosome and apoptosis. Eventually the macrophage dies
via necrosis, which is characterized by complete cell lysis, releasing bacteria and causing
further spread of infection24,26,28.
Delayed adaptive immunity
The increased necrosis and dissemination of the bacteria limits cross-presentation of Mtb
antigens by dendritic cells in the draining lymph nodes, thereby delaying the adaptive
immune response24,34. The migration of dendritic cells (DCs) to the draining lymph node
takes place 7-9 days after initial infection. During this time, the disseminating bacteria
migrate out of the lung to form other lesions in the body. These lesions are efficiently
cleared by splenic T cells. DCs take an additional 7-10 days to migrate from the draining
lymph nodes back to the lung tissue, thus allowing Mtb up to 21 days to establish infection
in the lung21,23,24,34. Even when antigen-specific IFN-y-producing T cells are present in the
lung tissue (after parenteral vaccination or adoptive T cell transfer), control of bacterial
replication and infection is only accelerated by 5-7 days21,23,24.
Antigen-specific lymphocytes are essential to control of bacterial burden. T-helper
(CD4+) cells are especially critical. Mice deficient in functional CD4+ T-helper cells
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cannot control replication and develop severe disease23,24,34–36. Similarly, HIV patients with
decreased CD4+ T-helper cells are at high risk for active TB and have increased TB
morbidity. Despite their necessity, the efficacy of lymphocytes is temporally and spatially
dependent, making it variable from patient to patient.
Many events may contribute to the delay of the adaptive immune response. In
addition to the aforementioned necrosis and subsequent dissemination, FoxP3+ CD4+ Tregulatory cells and the cytokine IL-10 may directly inhibit and delay T-helper cells23,24.
This delay may also be a mechanism of reduced phagocyte – lymphocyte contact. The long
migration time of T cells from the circulation back to the lung parenchyma allows innate
immune cells to continue to accumulate at the site of infection. Neutrophils and permissive
macrophages interfere with the critical interaction between CD4+ T cells and infected
macrophages, and they also decrease T cell effectiveness at controlling bacterial
burden21,24.
CD8+ T cells are also involved in the adaptive response to TB, although not to the
same extent as CD4+ T cells. In fact, the extent of their contribution to bacterial control is
somewhat controversial in the literature. CD8+ T cells migrate with CD4+ T cells into the
lung parenchyma. Here they mediate control of infection via two pathways: (1) secretion
of Th1 cytokines to recruit and activate phagocytes, and (2) the secretion of granulysin for
the direct killing of infected phagocytes24,37. However, CD8+ T cells alone are not sufficient
to control infection. Sud and colleagues demonstrated this by depleting mice of CD4+ T
cells and inducing CD8+ T cells to produce enough IFN-γ to match wild-type levels of IFNγ, and CD8+ T cells were not sufficient to control infection. In addition, when mice were
either depleted of CD4+ T cells or IFN-γ, mice without CD4+ T cells had earlier active
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disease progression37. This is also seen in humans, as CD8+ T cells are not sufficient to
clear disease in AIDS patients with TB co-infection.
Humoral immunity and innate lymphocytes
The benefits of humoral immunity in TB are widely debated. Considered ineffective in
controlling infectious burden early on in TB research, studies in this area were neglected
for years24,34,38–41. However, the limited protection provided by BCG worldwide and the
failure of vaccine competitors in clinical trials has re-invigorated humoral research as a
possible supportive mediator of TB immunity. Studies in B cell-deficient mice have shown
varied results ranging from increased susceptibility and diminished protection, to reduced
pathogenesis and dissemination, to no effect41–46. It is known that follicle-like B cell
aggregates, or inducible bronchus-associated lymphoid tissues, are found in the outer
portions of the pulmonary granuloma in chronic TB infection34,41,47. While their function
in TB still remains speculative, studies in mice challenged with pulmonary influenza virus
have shown these lymphoid-like structures are important mediators of protective immunity
and lymphocyte memory responses in mice lacking secondary lymphoid tissue41,48,49. In
addition, while B cell-deficient mice challenged with low-dose Mtb aerosol appear to be
unaffected by the loss of humoral immunity, high doses of Mtb aerosol or intravenous
injection in B cell-deficient mice produced increased lung pathology and disease
susceptibility34,42,46. Lastly, B cells have been shown to modulate infection via the Fcγ
receptors, where selective antibody engagement of the stimulatory Fcγ receptors or
inhibitory FcγRIIB receptor on APCs results in an increased Th1 response and bacterial
containment or IL10 production and diminished protection, respectively34,41,46. These data
seem to indicate that B cell involvement in TB infection is more complicated than initially
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thought, with many factors including infectious dose, stage, and location of Mtb all
affecting the role of humoral immunity.
Innate T cells are perhaps the newest additions to the field of TB immunity.
Mucosal associated invariant T (MAIT) cells, natural killer T (iNKT) cells, and γδT cells
have all been shown to play a protective role in tuberculosis, although to what extent
remains to be explored. MAIT cells are activated by the infection of airway epithelial
cells21,50. Activated MAIT cells can limit early bacterial growth and prevent infection
progression. iNKT cells become activated during primary infection and secrete
granulocyte-macrophage colony-stimulating factor (GM-CSF), which functions as a
cytokine, bringing immune cells into the lung21,51.

Similarly, γδT cells recognize

phosphoantigens on Mtb, triggering rapid clonal expansion. These cells secrete cytokines
and can directly kill Mtb-infected cells and can inhibit mycobacterial growth21,52.
Latent infection
After infection with Mtb, disease progresses in two possible ways. The first is that the
patient develops active TB. Mtb replicates in the lungs, unperturbed by the immune system,
and clinical symptoms develop including fever, weight loss, and flu-like symptoms. Within
the lung, severe tissue damage develops in areas of infection24. Alternatively, the patient
develops latent TB and has no clinical symptoms of infection. With one-third of the world
infected with Mtb, most individuals develop clinical latency, making the patient
asymptomatic and possibly unaware of the infection9. During latent infections, the
bacterium remains quiescent in the lungs, trapped in hypoxic granulomas and unable to
replicate24. Only 5-10% of individuals with latent TB progress to active TB during their
lifetime (termed re-activation), and these individuals are usually immunocompromised in
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some way9. Individuals with latent TB will commonly test positive in a skin test. The test
is performed by injecting purified protein derivative (PPD), or Mtb culture filtrate, directly
beneath the top layer of skin. The induration that forms is measured, and is generally larger
in individuals who have been exposed to the mycobacteria. Interestingly, individuals who
are latently infected but test negative in the skin test are more likely to progress to active
disease53. This is further complicated in individuals who are vaccinated with BCG and are
PPD+ due to the immunization.
The diagnosis of latent TB infection is dependent on an affirmative PPD or
interferon gamma release assay (IGRA; a blood test) in the absence of active disease. This
may be the result of bacterial clearance, or granulomas in the lung preventing bacterial
growth and disease progression. Granuloma structure is complex and multi-cellular.
Fibrotic tissue surrounds the outside of the granuloma and the center is formed by infected
phagocytes, neutrophils, multinucleated giant macrophages, epithelioid cells, and foamy
macrophages. A layer of lymphocytes and B cells surrounds the exterior of the
granuloma24,54. At the center of the granuloma a caseous necrotic core develops due to cell
lysis, creating a hypoxic environment where the bacteria remain dormant and unable to
replicate.
Granulomas were originally thought to be static structures, trapping bacteria within
the immune cell-comprised walls and preventing its dissemination. However work with M.
marinum in a zebrafish model looking at innate immune cells, as well as a study looking
at lymphocytes in TB granulomas in the livers of mice, showed that the granuloma is a
fluid structure with lymphocytes and macrophages moving throughout40,55–57. Thus, the
granuloma establishes an equilibrium within the host, with immune cells keeping the
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mycobacterial numbers constant and contained, while a small subpopulation continues to
replicate23,58. This idea of bacterial and immunological equilibrium seems to support the
clinical manifestation of extreme heterogeneity among granulomas, both within the lung
and between patients.
Correlates of protection and tolerance
Until recently, the immune correlates of protection during Mtb infection were all
proinflammatory, or Th1-differentiated.

As mentioned earlier, CD4+ and CD8+ T

lymphocytes are critical mediators of defense, as well as phagocytes and other innate
inflammatory responders (see Early Events of Infection and Delayed Adaptive Immunity).
IFN-γ and tumor necrosis factor α (TNF-α) are two well-known proinflammatory cytokines
present in the infected lung environment which are critical for control of the infection.
However, these cytokines have also been shown to have detrimental effects. IFN-γ is
mainly secreted by CD4+ cells in response to IL-12 secretion by Mtb-infected DCs. It can
also be secreted by CD8+ T cells, NK cells, γδ T cells, and alveolar macrophages24,59–61.
Mice without IFN-γ are extremely susceptible to Mtb infection and morbidity62,63. They
cannot control bacterial growth, have defective macrophage activation and function, and
fail to produce reactive nitrogen and oxygen species24,62–64. In addition, IFN-γ is crucial to
inhibit the secretion of possibly detrimental cytokines like interleukin 17 (IL-17), which
recruits neutrophils into the lung21. However, despite its essential role in reducing bacterial
burden, IFN-γ is a controversial correlate of protection. While the cytokine is produced in
healthy PPD+ patients, it has been shown that patients with active TB may have suppressed
levels64–67. This may be due to the ability of Mtb to inhibit IFN-γ signaling. This arguably
makes IFN-γ levels alone a poor predictor of disease outcome 64.
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TNF-α has been shown to modulate granuloma formation, maintenance, and
function68,69. In conjunction with IFN-γ, it mediates macrophage function and production
of reactive nitrogen and oxygen species64. Mice treated with anti-TNF-α antibodies exhibit
increased bacterial burden, disorganized granulomas, poor macrophage function and
activation, and increased regulatory-T cell (Treg) numbers23,61,70–72. However, despite the
documented antimicrobial effects of TNF-α, it has been shown that TNF-α is associated
with host-mediated lung pathology64,73–75.
More recently, a role for anti-inflammatory cytokines and mediators has been
implicated during TB infection; however, to what extent these cytokines are beneficial
versus harmful remains unknown. Tregs, interleukin-10 (IL-10), and transforming growth
factor β (TGF-β) are generally considered anti-inflammatory in nature, namely Th2- or
regulatory- differentiated. Unrestrained inflammation can cause severe pathology in the
lung, as mentioned above, so these anti-inflammatory cells and cytokines can be protective.
FoxP3+ Tregs interact with CD4+ T cells and can limit their effector function and
recruitment24. IL-10 deactivates macrophages, limits IFN-γ secretion, and suppresses
CD4+ T cell and APC function64,76,77. TGF-β can also deactivate macrophages and
suppress CD4+ T cell function, in addition to altering reactive nitrogen and oxygen species
production64,77–79. However unintuitive it may seem, these anti-inflammatory mediators
may be essential in preventing severe lung pathology as well as T cell exhaustion.
Programmed cell death protein 1 (PD-1) is a cell surface receptor expressed on activated B
and T cells24. When it binds to its ligands, programmed death ligand 1 and 2 (PD-L1 and
PD-L2), negative signal cascades inhibit cell proliferation and cytokine production24. PDL1 is induced during chronic inflammation, as shown by increased PD-L1 levels in patients
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with active TB compared to healthy or latently-infected patients24,80. Therefore, it appears
that anti-inflammatory immune mediators may have a role in preventing the detrimental
effects of unchecked inflammation, although too much inhibition of inflammatory
mediators may worsen disease.

Treatment of Mtb
For many, TB is a treatable infection. Beginning with the discovery of streptomycin in
1944, a steady stream of antibiotics were approved for TB treatment, ending with the
discovery of ofloxacin in 1980. Since then, antibiotic discovery has been largely
unproductive, with bedaquiline and delamanid being the only new approved TB antibiotics
in 40 years.
There are currently 14 drugs approved by the US Food and Drug Administration
(FDA) and/ or European Medicines Agency (EMA) for the treatment of TB (Table 1.2).
These antibiotics are always used in combination to mitigate drug resistance. Standard
treatment usually takes place over a six month time period and is antithetically referred to
as “short-course” anti-TB therapy81,82. For the first two months (initial phase), patients take
three to four of the first-line drugs. During the final four months (continuation phase), they
receive only rifampicin and isoniazid. Adding together the daily doses for a typical adult
patient equals more than one–third of a kilogram of the multidrug mixture (oral
administration) in a series of 182 total daily dosages82. Comparatively, uncomplicated
community-acquired bacterial pneumonia or similar infections take 2-5 grams in a series
of 5-7 total dosages82.
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The rise of antibiotic resistant Mtb
As previously stated, the same TB antibiotics have been used for decades, with only two
new TB antibiotic approved by the US Food and Drug Administration (FDA) in the last 40
years83 (Fig. 1.1). In 2014, 480,000 people developed multidrug-resistant TB (MDR-TB)
and it is estimated that 9.7% of these cases were actually extensively-drug-resistant TB
(XDR-TB)9. Even more terrifying were reports of the emergence of totally-drug-resistant
strains of TB (TDR-TB) in India beginning in 201184.
MDR-TB is defined as a strain of Mtb that is resistant to the two most powerful
first-line drugs, isoniazid and rifampin85. MDR-TB is treatable, but second-line drugs must
be used. These antibiotics generally have more severe side effects, longer treatment times,
and can cost up to nine times more than first-line antibiotic therapies (average of $150K
for MDR patient treatment versus $17K for drug-susceptible TB patient treatment in the
United States)86,87. If the TB strain develops further resistance to drugs in the second-line
therapies, specifically any fluoroquinolone and at least one of the three injectable drugs
(kanamycin, capreomycin, amikacin), then it is termed XDR-TB85. Patients with XDR-TB
have limited treatment options and complicated anti-TB regimens which are 28 times more
expensive than standard short course therapy ($480K for XDR patient treatment in the
United States)86,87. If the strain of TB develops resistance to all first- and second-line
therapies, the patient is diagnosed with TDR-TB, antibiotic options are minimal, and the
clinical outlook is grim.
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Figure 1.1 The race between antibiotic development and evolution of Mtb drug resistance. Antibiotic
development against Mtb has slowed over the past 50 years. Concurrently, Mtb drug resistance strains have
emerged, limiting treatment options for patients.
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Table 1.2 Antibiotics for treatment of TB

Drug

Year of
Discovery

First Line Drugs
Isoniazid
1952
(INH)
Pyrazinamide
1954
(PZA)
Ethambutol
1961
(EMB)
Rifampicin
1963
(RIF)
Second Line Drugs
Streptomycin
1944

Molecular Target

Effect

Enoyl-acyl carrier protein reductase

Inhibition of mycolic acid
synthesis
Inhibition of translation;
acidification of the cytoplasm
Inhibition of arabinogalactan
biosynthesis
Inhibition of transcription

S1 component of the 30S ribosomal
subunit
Arabinosyl transferases
Beta subunit of RNA polymerase

Para-amino
salicylic acid
Cycloserine

1948

S12 and 16S rRNA components of
the 30S ribosomal subunit
Dihydropteroate synthase

1955

d-alanine racemase and ligase

Kanamycin
Ethionmide

1957
1961

30S ribosomal subunit
Enoyl-acer carrier protein reductase

Capreomycin

1963

Amikacin
Ofloxacin

1972
1980

Bedaquiline

1997

Delamanid

2006

Interbridge B2a between the 30S
and 50S ribosomal subunits
30S ribosomal subunit
DNA gyrase and DNA
topisomerase
C-subunit of the F0 complex of
ATP synthase
Methoxy mycolic and ketomycolic
acid
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Reported
Resistance

Ref

yes

12,88,89

yes

12,90,91

yes

12,88,92

yes

12,88,93

Inhibition of protein synthesis

yes

12,88,94

Inhibition of folate biosynthesis

yes

12,95,96

Inhibition of peptidoglycan
synthesis
Inhibition of protein synthesis
Inhibition of mycolic acid
biosynthesis
Inhibition of protein synthesis

yes

12,97–99

yes
yes

12,100,101

yes

12,101,103

Inhibition of protein synthesis
Inhibition of DNA supercoiling

yes
yes

12,101,103

Inhibition of ATP synthase

yes

106–110

Inhibition of mycolic acid
synthesis

yes

109,111–113

12,88,102

12,88,104,105

Bacille Calmette-Guérin (BCG) vaccine
BCG is the only vaccine currently available against TB. It was produced more than a
century ago from a virulent strain of M. bovis using continuous in vitro passage to attenuate
the bacteria. Immediately after BCG’s creation, the first human newborns were vaccinated
in Europe in 1921, which led to significant protection against TB in young children114.
BCG’s success in Europe in the first half of the 20th century allowed it to expand to other
TB-endemic areas, notably in Africa and Southeast Asia. Since 1974, BCG is part of the
WHO Expanded Program on Immunization (EPI), and the estimated coverage in TB
endemic countries now exceeds 80%115. The growing world-wide demand for this live
vaccine led to different BCG strains with minor genetic differences being cultured and
passaged around the world. These strains were later classified as “early” strains (Russia,
Moreau, Japan, etc.), based on few gene deletions, and “late” strains (Tice, Danish, Pasteur,
etc.) that acquired further deletions due to the different culture mediums and growth
conditions used during BCG’s manufacturing process116. Currently, more than 13 different
BCG sub-strains have been reported117; however, none of these strains are fully effective
against the most prevalent form of the disease, adult pulmonary TB.
History of BCG delivery
After it was introduced in the 1920s, the BCG vaccine was initially administered to children
orally with milk, a route that Calmette and Guérin thought was crucial for BCG’s success.
The oral route was discontinued after the Lubeck disaster in Germany, where 67 infants
died after BCG vaccination. It was later recognized that the vaccine batch used to immunize
infants in Lubeck was contaminated with virulent strains of Mtb118. This incident gradually
led to the oral route of BCG delivery being replaced by the intradermal route, as the oral
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route was considered to be unsafe. In addition, the new parenteral route required only one
BCG dose, compared to 3 doses for oral immunization.
Since then, many other routes of BCG delivery have been attempted, including
intranasal, pulmonary (see pulmonary immunization for global protection), and even a
revival of the oral route119–125. The goal for most of these studies was to target the mucosal
immune system directly to provide better protection against pulmonary TB. Mittrucker et
al. observed comparable levels of protection in mice against aerosol challenge with Mtb
after oral and systemic BCG immunization. However, different levels of dissemination and
persistence of BCG were observed in various organs122. Others administered BCG orally
after encapsulating the live bacteria to protect it against the harsh gastric environment126.
Encapsulated BCG administered by the oral route achieved viable bacteria in the
mesenteric lymph nodes that correlated with protection against Mtb compared to
unencapsulated orally-administered BCG127.119–125. Importantly, no studied alternative
delivery routes have succeeded in replacing the parenteral route of BCG administration
that was adopted in the 1930s, in spite of the promising results obtained from alternative
routes of BCG administration.
Failures of BCG
Despite immunization efforts in over 150 countries worldwide, BCG has failed to reduce
disease burden in areas of the world where TB is endemic (Fig. 1.2). A study in 1979
conducted by the WHO followed individuals in a controlled-community trial in South India
for 7.5 years and found no evidence of the protective effect of the BCG vaccine128. This
was in contrast to initial trials in North America and the United Kingdom, which showed
80% protection in vaccinated individuals129,130. A later meta-analysis of the published
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literature showed that BCG provided an average of 50% protection, but the variability in
efficacy rates could be largely explained by geographical location131. The various
hypotheses for the inconsistent efficacy of BCG are as follows:

Figure 1.2 The global efficacy of BCG. The efficacy of BCG at protecting against Mtb varies
geographically. Countries shown in orange have effective immunization programs as measured by number
of Mtb infections. Countries shown in red have ineffective immunization programs. Countries shown in tan
do not vaccinate against Mtb.

Environmental mycobacteria
Efforts to understand the inconsistency of BCG protection have been numerous, varied,
and widely conflicting. One of the more common theories relates varied geographical
efficacy to the presence of high concentrations of EM in areas where TB is problematic.
EM, BCG, Mtb, and all other mycobacteria are remarkably alike, sharing similar protein
secretion pathways, cell wall components, and even similar 16S rRNA132–134. These studies
were initially linked to the South India trials, where high levels of EM, specifically
Mycobacterium avium-intracellulare-scrofulaceum (MAIS) complex, were isolated from
the environment and sputum of vaccinated individuals with symptoms of TB infection135.
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These studies were validated in multiple animal models of TB, showing chronic EM
exposure by the oral or parenteral route results in the modulation of the host response and
protective effects to BCG immunization136–140.
Speculation on the underlying mechanistic reasons behind the modulation of host
response to BCG after EM exposure remains varied and uncertain. Circulating theories in
the literature include the masking hypothesis and the blocking hypothesis, with large
amounts of evidence supporting both. The masking hypothesis was initially suggested in a
study by Palmer and colleagues, which showed that pre-sensitization with EM offered
some immunity against Mtb in guinea pigs, and later immunization with BCG conferred
little to no additional anti-mycobacterial immune response141,142. This was further
illustrated by later research which compared pre-mycobacterial immunity, via delayed-type
hypersensitivity (DTH) skin test response to tuberculin purified protein derivative (PPD),
of individuals in Malawi and the UK before and after BCG vaccination. The results showed
that individuals in the UK started with much lower pre-existing immunity to mycobacteria,
leading to a large increase in response after BCG vaccination. In contrast, individuals in
Malawi had high pre-existing immunity to mycobacteria, leading to very little increase in
immune response after BCG vaccination. The effect of prior EM immunity “masked” the
immunity gained by BCG vaccination, rendering BCG an ineffective booster of prior
mycobacterial immunity143,144 (Fig. 1.3A). The blocking hypothesis was suggested in a
study which looked at the replication of BCG in the lungs of vaccinated mice. Prior EM
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exposure resulted in immunity significant enough to “block” BCG replication, but not

Figure 1.3 Proposed mechanisms for BCG failure due to EM interference. A) Masking Hypothesis, and
B) Blocking Hypothesis. Y-axis depicts protective efficacy and x-axis depicts time exposed to the antigen.
Dashed line represents the arbitrary level of immunity. A) The masking hypothesis reasons that BCG
immunity required in an EM-exposed host never surpasses the immunity gained in response to EM-exposure
alone. B) The blocking hypothesis suggests that BCG is vulnerable to achieve protection against Mtb
existing mycobacterial immunity in an EM-exposed host and cannot remain long enough in the lungs to
generate BCG-specific immunity.

sufficient to block Mtb growth, which was unchanged by EM pre-sensitization136. This
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short-lived time-frame wherein BCG was present in the lungs was not considered sufficient
enough to generate a strong immune response (Fig. 1.3B).
BCG vaccine antigenicity
NTM exposure is not the only explanation for poor BCG protection. Many researchers
believe that the live vaccine itself is inconsistent. Since its origin in the laboratory of
Calmette and Guérin in the early 1900s, M. bovis was passaged over 230 times before
becoming the attenuated BCG first administered in 1921. The vaccine continued to be
passaged for maintenance because there was no cold chain storage or lyophilization. By
the time the first freeze-dried BCG stock was generated (the Pasteur strain in 1961), BCG
had been passaged over 1173 times145,146. As mentioned before, over 13 well-studied
strains of BCG exist, and all have different molecular and genetic fingerprints. Different
geographical regions of the world use different strains of BCG, and while each daughter
strain was originally produced to maintain attenuation as well as antigenicity, little is
known about which strains are the most effective.
Mtb strain virulence
There are many different strains of Mtb that have branched off this ancient bacteria’s
phylogenetic tree, and there are 6 main strains that infect different areas of the world147,148.
These strains are differentiated by large sequence polymorphisms (LSP), which suggest
where and when the strain emerged in the Mtb phylogeny. This is comparable to influenza
strains which are named for the area and year of a particular outbreak. Interestingly,
Gagneux and colleagues demonstrated that the host immune system can respond very
differently to different strains of Mtb147. For example, it has been shown that ancient
lineages of TB, when compared to more modern lineages, stimulate the innate immune
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response better. This may have evolved as a mechanism of virulence and spreading
efficacy. Ancient lineages are associated with low density areas of the world, and may have
evolved such that a robust innate immune response may have been beneficial to the
bacteria, allowing it to remain latent in its host for later spread. This is in contrast to more
modern strains of TB which infect population-dense areas of the world and seem to avoid
robust innate host immunity147,148. It has been speculated that these strains of Mtb suppress
innate immune functions because spread in these population dense areas is more likely.
These strain to strain differences in host immune response may be important to consider
when thinking about global differences in BCG efficacy.
Helminths
Another popular hypothesis which attempts to explain the poor protection associated with
BCG immunization is immune interference by helminth co-infection. Helminths share the
same geographical niches as TB, with the highest infection rates in Africa, Asia, and
Southern America. Helminths are an extremely diverse group of gastrointestinal parasites
which are acquired when food and water sanitation is poor149. These parasites alter the
immune environment of their host from a dominant Th1 response (proinflammatory and
cell-mediated) to a Th2 response (lymphocyte suppressive, mostly humoral immune
response). These responses can cross-regulate each other; Th2 cytokines suppress the
secretion of Th1 cytokines, thereby preventing the Th1 immune cell migration required to
protect against Mtb150.
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Other vaccine platforms
Live bacterial vaccines
Live bacterial vaccines induce immune responses either to the vaccine bacteria or to a
specific antigen expressed by the bacteria. They have the advantage of mimicking a natural
infection and eliciting a potent immune response to one or more of the expressed antigens.
In addition, live vaccines have intrinsic adjuvant properties to stimulate a strong immune
response151,152. Live bacterial constructs are an attractive vaccination strategy to enhance
the immune response. The survival of BCG vaccine in the host after immunization is
necessary for optimum immune induction145,153. Live BCG strains, compared to dead
bacilli, are critical for protection in mice against Mtb infection154,155. However, live BCG
is also known to cause local and disseminated complications, especially in
immunocompromised individuals. Various BCG sub-strains used in human vaccination
differ in the percentage of viable bacteria present at the time of vaccination, their capacity
to survive in the host after systemic administration, and the ability to produce antigens in
the host131,145. Yet no clinical trial has been conducted to specifically address the question
of BCG survival in vaccinated individuals and their probability of contracting TB. The goal
of any live bacterial vaccine is to be non-pathogenic to the host but still elicit a long-lasting
immune response. This could be achieved by: 1) attenuating the pathogenic bacteria- via
deletion of essential virulence factors156; 2) Developing stable auxotrophs - these are
bacteria that are not able to replicate or have limited capacity for replication in the
vaccinated individuals; or 3) Recombinant bacterial strains that overexpress Mtb antigens
or proteins that are known to generate a potent anti-mycobacterial immune response. These
antigens are known to work by different mechanisms; one of them is to allow the live

25

vaccine to escape the phagolysosome into the cell cytoplasm to generate a strong CD8+ T
cell response157.
Safety concerns of live vaccines
In spite of the above safety checkpoints of live bacterial vaccines, the risk of conversion
from the avirulent to virulent state, thereby increasing the probability of causing disease,
still exists. Other safety fears with live bacterial vaccines include systemic infection,
dissemination to organs, induction of tolerance to a specific or related bacterial strain used
for vaccination, potentiation of autoimmunity, gene/plasmid transfer to host’s indigenous
flora, suppression of the indigenous flora due to competition, and transfer of the live
bacterial vaccine to other individuals.
Integration of a mycobacterial antigen-encoding plasmid into a live recombinant
vaccine could be a potential hazard. It is possible that the altered vaccine strain could
horizontally transfer the plasmid to other bacteria present in the vaccinated individual. This
could lead to the undesirable persistence of the plasmid in the host. However, humans are
constantly exposed to pathogenic and non-pathogenic bacteria without significant damage.
These bacterial exposures usually happen by either the oral and/or the pulmonary route,
rather than the parenteral route by which most immunizations are administered. The route
of vaccine administration could therefore be a critical factor when evaluating this specific
hazard158. Many of the above safety concerns could be mitigated by the dose, regimen
(single or multiple immunizations), and route of delivery. Although live vaccines continue
to show significant promise in preclinical and early clinical trials, sufficient safety studies
are required to gain the confidence of world regulatory agencies to move forward with any
live TB vaccine159.
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Inactivated whole-cell vaccines
The role of inactivated vaccines is to mimic a natural infection, allowing the human body
to generate its own protective immunity, similar to that of a live-attenuated vaccine
(discussed in Safety concerns of live vaccines). However, unlike with live bacterial
vaccines, there is no fear of dissemination or infection from an inactivated whole-cell
vaccine. In a study by Vuola et al, five doses of inactivated Mycobacterium vaccae induced
durable cellular immune responses in HIV-positive individuals160; the local and systemic
reactions to M. vaccae were milder and less frequent than those normally observed with
BCG, implicating it as a safer vaccination strategy161. Moreover, the T-cell responses in
these HIV-infected patients were maximal in recipients who were earlier primed with
childhood BCG immunization162, thus making the inactivated whole-cell mycobacterial
vaccine a well-tolerated prime-boost immunization strategy in HIV-infected persons163.
However, the delay in implementing inactivated mycobacterial vaccines from clinical trials
to the clinic itself could be due to the multiple dose immunizations required to elicit a
protective immune response, especially in immunocompromised individuals.
Viral vector-based TB vaccines
Viruses such as pox virus, adenovirus, flavivirus, and lentivirus have been used as vectors
for antigen delivery as vaccines for various infectious diseases. Viral vector-based vaccines
are known to generate robust cellular immunity. Recombinant adenoviral vectors are potent
inducers of cellular immunity, especially HLA class I- restricted CD8+ T cell responses164.
For viral vector-based vaccines against TB, dominant Mtb subunits are expressed in these
vectors and have been evaluated as heterologous boosters in BCG primed individuals. Such
vaccines have been used for both pre-exposure administration in infants and post-exposure
administration in adults.
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MVA85A/Aeras-485 vaccine is a modified Vaccinia Ankara (MVA) construct
expressing the immunodominant antigen Ag85A that is shared between both Mtb and
BCG. MVA85A recently completed a phase 2b clinical trial in South Africa. This vaccine
was given to 4-6 month old infants as a boost to BCG vaccination given at birth. However,
MVA85A failed to provide protection at a 2 year follow-up compared to the group that
only received BCG vaccine165. Surprisingly, this vaccine induced all the known predictors
of vaccine protection studied in animal models against TB. These immune correlates
included Mtb-specific CD4+ T cells and mononuclear cells producing IFN-γ,
proinflammatory cytokines such as IL-2 and TNF-α, and increased Mtb-specific Th-17
cells. Prior to clinical trials, MVA85A vaccine was studied in various animal models
including mice, guinea pigs, non-human primates (NHP), and cattle166–169. Similarly, in
preclinical studies the vaccine provided protection against TB. However, the
immunological correlates of protection generated in these small and large animal models
could not be replicated in MVA85A-boosted infants. It is possible that the immature and
weak immune system of infants, which has yet to develop polyfunctional T cells against
Mtb antigens, could not generate the robust response to immunization required to
effectively protect against TB infection. Since the majority of individuals contract TB
during their adolescent years when the immunity of BCG is waning, viral vector-based
vaccines should be evaluated in an adult population.
In a phase I clinical trial in BCG-vaccinated South African adults, another viral
vectored vaccine (adenovirus-based), Crucell Ad35/ Aeras-402, induced robust and
polyfunctional CD4+ and CD8+ T cells170. Recently, Aeras-402 was also evaluated as an
inhaled vaccine in NHPs after Mtb aerosol challenge171. Although the vaccine generated a
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robust cellular immune response in the lung compartment, it failed to provide protection
against a high Mtb challenge dose. This study again showed the disparity between immune
correlates and protection provided in the host. Adenoviral-based vaccines also exacerbated
infection in HIV patients, thus making them more susceptible to AIDS. Therefore, the use
of adenovirus based vaccines in an HIV-TB co-infected patient needs to be reevaluated172–
174

.

Heterologous prime-boost vaccination strategies in TB
The boosting of immunity against infectious diseases during the lifetime of an individual
is not a novel concept. Adults are more susceptible to TB as BCG-induced protection wanes
with time after childhood immunization. However, TB booster immunizations are
ineffective in extending the protection afforded by BCG given at birth. TB vaccine
development has therefore focused on developing i) a successful vaccine to boost
individuals who were immunized with BCG in early childhood, and ii) a strong prime
immunization strategy that is receptive to multiple boosters during an individual’s lifetime.
This should include a prime childhood immunization and a booster vaccine, both
expressing latent TB antigens. This would improve the immunity in more than 2 billion
adults with apparent latent TB infection to prevent future reactivation175. The risk of
developing latent TB infection increases by more than 60% in immunized adults in TBafflicted Sub-Saharan African countries176.
Subunit vaccines have been proposed as a booster to either BCG, recombinant
BCG, or attenuated Mtb vaccine in order to maintain high levels of immunity in the roughly
10% individuals vulnerable against TB during their lifetime177. Subunit vaccines can be
delivered either via viral vectors or as recombinant proteins mixed with adjuvants. Subunit
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vaccines in clinical trials include the M72 vaccine in AS01E adjuvant178, and hybrid 56
(ESAT-6 and Ag85B fused with the dormancy antigen Rv2660; see below)179.
A number of heterologous prime-boost immunization approaches have been
evaluated in animal models and human trials, with BCG given typically as the prime
vaccine. The initial development of BCG from M. bovis led to the deletion of the Region
of Difference (RD1) that encodes at least 9 antigens that are present in Mtb. Two of the
early secretory proteins missing from BCG, ESAT-6 and CFP10, are recognized by T cells
from almost all TB patients180. In addition, the non-replicating persistence of Mtb during a
latent infection allows the mycobacteria to express and upregulate latency genes181,182.
BCG does not express these latency antigens since it does not enter into a state of dormancy
after immunization. Therefore, BCG does not induce an immune response in the host to
the latency antigens183. To address this, attempts have been made to express some of these
latency antigens in recombinant BCG184. The authors observed long-term protection in an
aerosol challenged mouse model. BCG-primed animals, including NHPs, were boosted
with subunit vaccines containing ESAT-6. The subunit vaccine provided a strong
protective immune response and subsequent protection in these animals against aerosol
Mtb challenge185,186. In a recent study, post-exposure immunization of mice with ESAT-6
containing subunit vaccines prevented reactivation of TB, whereas BCG only did not
provide protection187.
The timing of booster dose(s) delivery must also be considered. In animal studies,
booster immunization is often performed quickly due to costs associated with animal
housing. However, a boost immunization should be delivered after the host develops a
memory immune response and should be timed based on trials in BCG primed children188.
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The route of boost vaccination is also critical for generating a strong immune
response in the host. It is evident that parenteral boosting with viral vector-based vaccines
has been less effective than respiratory mucosal boosting189. All TB candidate booster
vaccines currently in clinical trials are being evaluated by the parenteral route190. However,
parenteral boosting in BCG-primed infants was ineffective in a recent Phase 2b trial165.

Figure 1.4 Biomimickry: Using natural Mtb infection to inform vaccine design. Mtb infection naturally
occurs by the pulmonary route. While BCG mimics Mtb by sharing antigenic similarities, it is currently
given by the intradermal route which does not mimic the natural infection route. Administering BCG by the
pulmonary route would more naturally emulate infection, and hopefully provide better long-term protection.

Pulmonary immunization
Biomimicry: harnessing natural immunity for protection against TB
According to Janine Benyus, biomimicry involves using elements of nature for solving
complex human problems191. Biomimicry, in the realms of an immunization strategy,
would consist of emulating nature in developing and administering vaccines that resemble
natural infection. We have been using biomimicry in the field of immunization ever since
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Jenner developed a vaccine against smallpox.

However, natural exposure to such

pathogens usually occurs by the pulmonary, nasal, gastrointestinal, or reproductive mucosa
(Fig. 1.4). It may be that the use of attenuated bacterial strains for immunization, without
the integration of a natural exposure route, may not be sufficient to generate a robust and
long-lived immunity against a pathogen. Furthermore, using biomimicry to inspire
immunization platforms ensures that there is protection at the port of pathogen entry192.
Pulmonary immunization for global protection
While hopes for global vaccination against TB have been fraught with disappointment,
researchers have tried to change the route of immunization and/or add boosters to increase
protection. The pulmonary route of immunization may alleviate many of the current
failures of BCG. It seems logical that the airway would provide the best tissue platform for
vaccination as it is the entry site for Mtb infection, and vaccination via this delivery route
would mimic infection elegantly193. Multiple studies have shown increased protective
efficacy via the pulmonary route in various animal models of TB125,171,194–198. GarciaContreras et al. examined BCG vaccination efficacy by aerosol and showed a 2-log
reduction of Mtb burden in the lungs of guinea pigs compared to intradermal vaccination
alone123. Even more supportive is research published by Xing and colleagues comparing
intranasal immunization to classical intramuscular immunization (Fig. 1.5A&B).
Intramuscular vaccination failed to generate immune cells in the airway of the lungs of
mice, only generating adaptive immunity in the systemic lymph tissues and lung
parenchymal tissue. Conversely, immunization via the airway was able to generate immune
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cells in the airways of mice, which proved protective upon challenge of the mice later in
the study121,192,199.

Figure 1.5 The effect of immunization route on immunity in the airway. A) Intradermal immunization
generates T cells which migrate into the systemic circulation and lung parenchyma. However no immunity in
the airway is generated. B) Pulmonary and intranasal immunization generate T cells which migrate to the
systemic circulation, lung parenchyma, and the airway.
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In addition, pulmonary vaccination has the added benefit of eliciting localized
immunity in the form of resident memory T cells (TRM). Multiple groups have shown that
DCs from specific tissues have the ability to impart tissue-specific homing chemokines to
T cells, such that they will reside and home to the specific tissue where they first
encountered the antigen197,200–202. Antigen-specific T cells migrate to inflammation
regardless of origin, but TB is associated with a notably long delay in T cell migration into
the lungs (see Delayed Adaptive Immunity). Having TRM cells present in the lung when
infection begins may increase the speed in which T cells respond197.
Safety concerns for pulmonary immunization
As mentioned above, pulmonary immunization against TB has been evaluated for
feasibility and efficacy studies in animal models and has shown better protection compared
to parenteral immunization. However, pulmonary immunization against TB has not been
able to cross regulatory hurdles due to the risk associated with this delivery route. Recently,
a phase I safety and immunogenicity study was undertaken in BCG-vaccinated healthy
adults with the MVA85A vaccine delivered as an aerosol203. In this study, the pulmonary
route was well-tolerated with only mild adverse respiratory events observed. Future studies
should include a larger cohort of individuals to assess the pulmonary route of vaccination.
Role of adjuvants
There is a need for the development of effective and safe adjuvants that could be delivered
by the pulmonary route. Very few adjuvants are approved for human use and none of them
for pulmonary delivery. The adjuvants used for parenteral vaccines, including alum, are
not safe for pulmonary delivery193. Muramyl dipeptide (MDP) and trehalose dibehanate
(TDB) were evaluated in in vitro studies for use as an adjuvant in inhaled TB vaccines60.
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However, many pulmonary immunization studies use vaccines that have inherent adjuvant
properties, including live bacterial and viral vector-based vaccines.
Live versus dead vaccines
The safety concerns of live vaccines administered by the parenteral route are discussed in
an earlier section (see Safety concerns of live vaccines). Delivering a live vaccine by the
pulmonary

route

could

lead

to

dissemination

and

disease,

especially

in

immunocompromised individual. However, different doses of live BCG were safely
administered by the pulmonary route in cancer patients without any major side effects204.
BCG was well-tolerated in metastatic lung cancer patients with symptoms consisting of
transient chills for 4-8 hours post-BCG aerosol delivery. In addition, rhesus macaques were
vaccinated by the pulmonary route with a replication-defective recombinant adenovirus
(rAd; AERAS-402) expressing the Mtb antigens Ag85A and TB10.4171. The AERAS rAd
is a safe vaccine delivery vector due to its non-replicating nature and was suited for
pulmonary immunization due to its natural tropism for the respiratory tract205.
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Table 1.3 Different vaccines against TB in pre-clinical trials
Vaccine type

Antigens

Adjuvant

Formulation

Route of
Administration

Animal
Model

BCG
BCG

None
None

Dry powders
Sodium alginate MPs

Pulmonary
Oral

Guinea pigs
Mice

BCG

None

Lipid formulation

Oral

Mice

Aeras 402/Crucell Ad35
Ag85A, Ag85B, TB10.4

None

Dry powders

Pulmonary

‐

MVA (modified vaccinia
virus)

None

Nanopatch microneedle

transdermal

‐

Ag85B‐MPT‐64‐Mtb8.4

Incomplete Freund’s
adjuvant

Chitosan MPs

S.C.

Mice

DNA (hsp65)

Trehalose dimycolate

PLGA MPs

I.M.

Ag85B
DNA (hsp65)
DNA (Ag85B+MPT64
+MPT83)
Ag85A
DNA Ag85B
Ag85A
DNA‐HLA‐A‐0201
DNA‐Rv1733c
Bacteriocins
Trehalose dibehanate
DNA (hsp65)
ESAT‐6
Ag85B‐ESAT6
RUTI (detoxified cellular
fragments of M. tb)

Trehalose dimycolate
Trehalose dimycolate
Dimethyl dioctyldecyl
ammonium bromide
CpG
None
CpG
None
None
None
CAF01
None
CAF01
CTA‐DD/ISCOMs

PGLA MPs
PLGA MPs

Pulmonary
I.M.

Guinea pigs,
Mice
Guinea pigs
Mice

PLGA MPs

I.M.

Mice

Poloxamer 407 NPs
Chitosan NPs
Pluronic stabilized NPs
Chitosan NPs
PLGA‐PEI NPs
Liposomes
Liposomes
Liposomes
Liposomes
Liposomes

Pulmonary
S.C.
Pulmonary
Pulmonary
Pulmonary
I.V.
S.C.
Intranasal, I.M.
S.C.
Intranasal

Mice
Mice
Mice
‐
Mice
Mice
Mice
Mice
Mice
Mice

Liposomes

S.C.

‐

Ref

Whole cell vaccines
Live
attenuated
bacteria

Viral‐vectored

123
126
206
207

208

Subunit vaccines

Gene or
based

Antigen

209

210

211
212
213

214
215
216
217
218
219
220
221
222
223
224

None
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Dry powder vaccines
Dry powder vaccines and therapeutics are become an increasingly attractive alternative in
the field of inhaled pharmaceutics. Compared to liquid vaccine formulations, they have the
advantages of a long shelf-life and thermostability225–227. Similarly, when compared to
lyophilization, or freeze-drying, spray-dried powders can be easily designed for direct
pulmonary inhalation. Lyophilization requires many diluents not suitable for pulmonary
administration, and particle sizing is harder to control. Size is an important factor in the
design of particles for the lung. In order to reach the deep lung, particles must be 1-5µm in
diameter. Anything larger than this will impact on the back of the throat, and particles
smaller than this will be exhaled.
Table 1.4 Advantages and disadvantages of lyophilization and spray drying of vaccine formulations

Technique

Advantages

Disadvantages

Lyophilization

- Established method in
vaccine field
- Aseptic processing
- Limited process losses

-

Spray drying

- Controllable product format
- Easy to scale up
(Continuous processing
method)
- Customizable for different
delivery routes
- No freezing
- Particle is encapsulated (i.e.
particle engineering)

Adapted from McAdams et al.225
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-

Limited product formats
Requires reconstitution
Freezing step
Difficult to scale up (batch
process)
Time consuming
Energy usage
requirements
Process losses
Not well-established in
vaccine field
Aseptic processing more
difficult
Lack of regulatory
precedent

Perhaps one of the greatest advantages of dry powders is their versatility. They can
be formulated specifically to the antigen which they encapsulate to provide stability,
increased flow properties, and even superior antigenicity.
Spray drying
The spray drying method was first patented in 1901 by Robert Stauf for the production of
dried milk, blood, and other complex liquids225,228. Today, the process is a well-established
method of producing a dehydrated powder from a liquid solution or suspension225.
Specifically, a dry inert gas is pulled into the dryer and heated (Fig. 1.6B, 1&2). The liquid
solution is forced into the dryer via a peristaltic pump (Fig. 1.6B, A) and atomized with
the heated gas (Fig. 1.6B, B) in the spray dryer nozzle (Fig. 1.6B, 3). The atomized liquid

Figure 1.6 The spray drying process. (A) The Buchi mini spray dryer-290, (B) A Schematic of the
spray drying process. Images adopted from: Buchi229 and Pelkonen322.

droplets are dispersed into the drying chamber (Fig. 1.6B, 4), which is filled with the heated
gas. As the droplets fall through the dying chamber, the solvent from the solution begins
to dry and concentrates the dissolved/suspended material. The dried particles pass through
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a bridging tube (Fig. 1.6B, 5) where the temperature of the drying gas is measured (outlet
temperature). The temperature of the particles will be less than or equal to the outlet
temperature due to evaporative cooling. From the bridging tube, the particles are pulled
into the cyclone, where the drying gas and the particles are separated using particle inertia
(Fig. 1.6B, 6). The drying gas is taken away (Fig. 1.6B, 7), filtered, and released into the
atmosphere, and the particles are collected into a powder collection vessel (Fig. 1.6B, 8).
Part of the customizability of spray-dried powders is derived from the process itself.
Throughout the procedure there are parameters which can be varied to achieve a particular
powder. Some of these parameters and their effects are shown in Table 1.5.
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Table 1.5 Effect of spray drying process parameters on dry powder characteristics

Adapted from Buchi Mini Spray Dryer B-290 Manual229
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Excipient selection
Another customizable component of spray-dried powders is derived from excipient
choice. The word excipient is derived from the Latin word excipere and means “to
except”. In simplified terms, an excipient is anything other than the active ingredient230.
Excipients are selected based on the route of delivery and are added to a formulation to
improve its structural integrity and extend shelf-life. Over the decades, various excipients
have been evaluated to enhance stability227,231–239.
TB vaccines currently being evaluated in preclinical and clinical trials are mostly
liquid formulations and are at risk of chemical and physical degradation. For a liquid
product, stability will depend on the solution pH, ionic strength, redox potential, and the
temperature at which it is stored. The pH effects the rate of enzymatic activity of live
attenuated bacterial and viral vaccines240. However, the inclusion of excipients can
stabilize vaccines by different mechanisms, including buffering against pH or hydration
changes (non-reducing sugars such as trehalose, mannitol, sucrose, etc., and amino acids
such as leucine, lysine, glycine, etc.), and decreasing adsorption and aggregation (nonionic surfactants). The combined effect is to prevent protein interactions due to steric
hindrance by different molecular weight polymers and serum albumins.
Thermostability
A thermostable vaccine does not require cold-chain storage and maintains potency for
extended periods when exposed to extreme temperatures. The importance of thermostable
vaccines was first demonstrated during the global eradication of smallpox. Leslie Collier
was credited with developing a “heat-stable” smallpox vaccine using novel excipients in
conjunction with the lyophilization process, allowing the vaccine to be stable at 37°C241.
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The WHO initiated the global smallpox eradication campaign in 1967, leading to
complete eradication of smallpox in 1980242.
Most vaccines currently on the market require continuous cold-chain storage (28°C) to remain effective. The temperatures in some tropical countries can exceed 45°C
on a hot summer day. Therefore, thermal stability is important for the manufacture,
distribution, and administration of vaccines. Similarly, a loss in potency can occur due to
freezing conditions. Failures to maintain regulated temperature conditions are observed in
the supply chain from the point of production (usually in high-and-middle income
countries) to the point of administration (usually in resource-poor countries). At present,
one in five children do not receive some of the prescribed vaccines under the Expanded
Program on Immunization (EPI) due to the absence of a robust cold-chain system243.
Future vaccines need to be stable at extreme temperatures to ensure better product
stability leading to a longer shelf-life. Wong et al. spray-dried BCG with leucine as an
excipient and demonstrated four months stability at 25°C244. Jin et al spray-dried
adenovirus-vectored vaccine (Aeras 402) using non-reducing sugars and the viral stability
was observed for 12 months at 4°C and 25°C, and also for five weeks at 37ºC207. These
authors show that a dry powder solid-state formulation provides enhanced thermostability
compared to the traditional liquid formulation.
A number of physicochemical assays including absorbance and fluorescence
spectroscopy, circular dichroism, and glass transition temperature (Tg) are used to
monitor changes to antigen and excipients undergoing the stresses of temperature, salt,
and pH245. The Tg is defined as the temperature below which the molecular mobility of
the product (consisting of any bound water, antigen, and excipients) approaches zero. Tg
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is usually determined using differential scanning calorimetry (DSC). Tg is important to
preserve the amorphous nature of a dry powder solid-state vaccine. A high Tg is thus
critical to ensure that the final product does not crystalize and maintains efficacy.
Excipients that promote a high Tg are ideal. Jin et al. formulated adenoviral-based TB
vaccines using a combination of excipients (mannitol, trehalose, cyclodextrin, and
dextran) to produce a Tg of >97°C after spray drying 207.
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Abstract
Bacille Calmette–Guérin (BCG) is currently the only approved vaccine against
tuberculosis (TB) and is administered in over 150 countries worldwide. Despite its
widespread use, the vaccine has a variable protective efficacy of 0-80%, with the lowest
efficacy rates in tropical regions where TB is most prevalent. This variability is partially
due to ubiquitous environmental mycobacteria (EM) found in soil and water sources, with
high EM prevalence coinciding with areas of poor vaccine efficacy. In an effort to elucidate
the mechanisms underlying EM interference with BCG vaccine efficacy, we exposed mice
chronically to Mycobacterium avium (M. avium), a specific EM, by two different routes,
including the oral and intradermal (ID) route, which mimics human exposure. After
intradermal BCG immunization in mice exposed to oral M. avium, we saw a significant
decrease in the proinflammatory cytokine IFN-γ and an increase in T regulatory cells and
the immunosuppressive cytokine IL-10, indicating oral tolerance. To circumvent the
immunosuppressive effect of oral M. avium exposure, we vaccinated mice by the
pulmonary route with BCG. Inhaled BCG immunization rescued IFN-γ levels and
increased CD4+ and CD8+ T cell recruitment into airways. Pulmonary BCG vaccination
was further examined in an aerosol challenge model of TB and proved protective regardless
of previous M. avium exposure. In conclusion, our data indicate that vaccination against
TB by the pulmonary route increases BCG vaccine efficacy by avoiding the
immunosuppressive interference generated by chronic oral exposure to EM. This has
implications in TB-burdened countries where drug resistance is on the rise and health care
options are limited due to economic considerations. A successful vaccine against TB is
necessary in these areas as it is both effective and economical.
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Author summary
The current vaccine against tuberculosis (TB), BCG, has variable efficacy (0-80%) at
protecting against infection. A large body of clinical and experimental evidence implicates
host exposure to environmental mycobacteria (EM) as the cause of interference with BCG
vaccine-induced immunity. We explore the mechanism by which EM interferes with
parenteral immunization and propose oral tolerance as a mechanism for this interference.
In addition, we use the pulmonary route to vaccinate EM-exposed hosts thus ensuring
effective BCG immunization and subsequent protection against TB. This work has broad
implications in the TB vaccine field as it shows that the vulnerability of the current vaccine,
and that of many novel vaccine candidates, may be the route of administration and not
necessarily the vaccine itself.

Introduction
Tuberculosis (TB) is one of the leading causes of death due to an infectious agent
worldwide, with a yearly mortality of 1.5 million9. The World Health Organization
estimates that over one-third of the global population is latently infected with
Mycobacterium tuberculosis (Mtb), the bacterium that causes TB, and every year 9 million
people develop active TB. These mortality and morbidity statistics, coupled with
increasingly limited antibiotic options due to drug resistance, demonstrate why an effective
vaccine against TB has become a global health priority9.
Bacille Calmette-Guérin (BCG) is the only approved vaccine against TB. Despite
widespread use, BCG offers variable protection against pulmonary disease (0-80%), with
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the lowest efficacy in geographical regions where TB is most prevalent140. This variability
is due, at least in part, to environmental mycobacteria (EM) exposure128,135–140. EM are
present ubiquitously in soil and water sources around the world, with high concentrations
coinciding with areas of poor vaccine efficacy18,19,246. Individuals living in these areas have
high EM exposure via the gastrointestinal (GI) tract18. While EM interference with BCG
protection has been widely studied, the mechanism of action has not been elucidated and
continues to be a topic of debate136,140,144,177,247.
To elucidate the mechanism of interference by EM, it is necessary to understand
how the immune system responds to EM and BCG, separately and together, in the
appropriate tissue of exposure. Homeostasis, inflammation, and tolerance are all critical
for protection against, and recovery from, pathogens202,248–250. This regulation of immunity
is different depending on the location of infection within the body. Localized infections are
usually compartmentalized to a specific tissue or niche within the body that favors
pathogenesis. Similarly, various tissues within the body can be immunologically primed to
home immune cells in a tissue-specific manner, such that these cells manifest their effects
primarily in a particular tissue compartment192,248,251. Thus, the route of exposure to an
antigen predisposes an individual for all subsequent immune responses to the same antigen.
Compartmentalized immunity is an evolutionary advantage. For example, the GI tract
needs to respond to pathogens differently than the respiratory tract. The GI tract comes into
contact with many pathogens daily and requires mechanisms for generating a tolerogenic
response to commonly ingested antigens and pathogens, in order to prevent unnecessary
inflammation

252–255

. This phenomena, called oral tolerance, is defined as the lack of a

systemic immune response to parenteral immunization with an antigen to which an animal
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has previously been exposed to through the GI tract254. Conversely, the lung and airway
are vulnerable to serious infection. The airway is a highly compartmentalized and reactive
tissue. This was illustrated by Xing and colleagues, who demonstrated the failures of
systemic vaccination against pulmonary pathogens like Mtb199,256,257. They showed that
parenteral vaccination with BCG was not sufficient for the recruitment of antigen-specific
immune cells to the airway of the lung in a mouse model of TB. Only mucosal (intranasal)
immunization generated immune cells in the airway and was protective against subsequent
aerosol Mtb infection257,258.
In the present study, we explored the oral and parenteral routes of EM exposure and
their ability to interfere with intradermal BCG immunization. We hypothesized that
chronic EM exposure by the oral route results in systemic tolerance toward these EM. We
found that this tolerance is cross-specific to the intradermally delivered BCG vaccine
which has cell wall components markedly similar to EM. Consequently, the host does not
generate immunity against BCG, and individuals remain vulnerable to TB infection.
Furthermore, we found that targeting the immunologically naïve airway by pulmonary
immunization circumvented systemic EM immunosuppression and provided BCG-specific
immunity which was protective against TB. Our research helps define the mechanism of
EM interference with BCG vaccination and indicates that pulmonary administration
enhances the protective effects of the BCG vaccine, regardless of prior EM exposure. It is
likely that these findings will also be pertinent to future TB vaccines containing
mycobacterial antigens that are administered by the parenteral route.
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Results
Murine T cells are cross-specific to EM and BCG
To validate EM suppression of parenteral BCG immunization responses, we exposed
C57BL/6 mice to M. avium (a species of EM) by oral gavage a total of eight times over a
four-week period (Fig. 2.1A). The exposure regimen was designed to mimic chronic
human exposure to EM by ingestion. Mice were rested for one week after the last M. avium
exposure and then immunized with BCG by the intradermal route, which is the current
immunization route in humans. Treatment groups included i) oral M. avium exposure and
no subsequent BCG immunization (O-MA), ii) intradermal BCG immunization without
prior M. avium exposure (ID-BCG) or iii) oral M. avium exposure followed by intradermal
BCG immunization (O-MA + ID-BCG). Mice were sacrificed one week after BCG
vaccination (6 weeks after initial M. avium exposure). Mouse spleens and lungs were then
harvested and T cells from these tissues were assessed for IFN-γ production after
restimulation with heat-killed BCG or M. avium.
T cells were first assessed for antigen cross-reactivity to determine whether
lymphocytes from EM-presensitized mice can distinguish between EM and BCG and thus
respond differentially. T cells from O-MA and ID-BCG mice were restimulated with either
heat-killed M. avium or BCG. There was no difference in IFN-γ response with respect to
the antigen (M. avium or BCG) used for restimulation (Fig. 2.1B), suggesting marked
antigenic similarity between M. avium and BCG. However, T cells from ID-BCG animals
responded with higher IFN-γ secretion than T cells from O-MA animals. Specifically,
when restimulated with BCG, T cells from ID-BCG mice secreted high levels of IFN-γ
(1x103 pg/mL), whereas T cells from O-MA mice secreted two-fold less (Fig. 2.1C).
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Importantly, mice presensitized with oral M. avium before intradermal immunization with
BCG (O-MA + ID-BCG) had markedly reduced IFN-γ secretion compared to the ID-BCG

Figure 2.1 Differences in cytokine response to BCG immunization were observed between mice that
were or were not presensitized to oral M. avium prior to intradermal BCG vaccination. (A)
Experimental design. Arrows indicate M. avium exposure. (B) Interferon-gamma (IFN-γ) secretion in
response to restimulation of splenic and lung T cells from mice exposed to either intradermal BCG or oral
M. avium with either heat-killed whole BCG or M. avium, n=6. (C) IFN-γ secretion in response to heatkilled whole BCG antigen restimulation of splenic and lung T cells from different treatment groups, n=6.
(D) Interleukin-10 (IL-10) secretion in response to BCG restimulation of splenic and lung T cells from
groups intradermally immunized with BCG with and without oral M. avium presensitization, n=4. A MannWhitney U test or multiple t-tests (Holm-Sidak) were used for comparison of two data sets, and a one-way
ANOVA Kruskal-Wallis with Dunn’s multiple comparison post-test for multiple data sets. *p<.05; **p<.01;
data shown with standard error of the mean (SEM).

group. Indeed, pretreatment with oral M. avium reduced IFN-γ secretion by T cells from
BCG-immunized mice restimulated with BCG to the level seen in mice never immunized
with BCG (O-MA only). Likewise, BCG stimulated lung T cells from mice orally exposed
to M. avium prior to intradermal BCG immunization (O-MA + ID-BCG) secreted IFN-γ at
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levels similar to that of mice treated with oral M. avium alone (Fig. 2.1C). These data
confirm previous findings and show that while intradermal BCG induces a strong
proinflammatory response in mice, the proinflammatory response to oral M. avium
exposure is limited139,140. Moreover, mice presensitized to oral M. avium and immunized
with BCG responded like unimmunized mice receiving only oral M. avium. Thus, oral
exposure to M. avium markedly suppressed the IFN-γ response to BCG restimulation.
Increased tolerogenic immune profiles associated with oral EM exposure
Decreased IFN-γ in mice exposed to M. avium suggested that O-MA suppresses the Th1
response to the BCG vaccine. To further assess the Th1-suppressive effect of EM oral
exposure on intradermal BCG immunization in mice, we also assessed differences in T cell
production of the proinflammatory cytokine TNF-α and the anti-inflammatory cytokine IL10 following restimulation with BCG. Interestingly, the only significant difference
between ID-BCG and O-MA+ID-BCG mice was seen for IL-10. TNF-α was not detectable
(data not shown). M. avium exposure prior to BCG immunization (O-MA+ID-BCG)
increased T cell IL-10 production nearly 30-fold and 20-fold in spleen and the lung,
respectively, as compared to T cells from BCG vaccinated naïve mice (ID-BCG) (Fig.
2.1D). IL-10 is an anti-inflammatory cytokine that is mainly secreted by regulatory T cells
(Treg), which are critical for lymphocyte suppression and known mediators of oral
tolerance. Furthermore, IL-10 is often increased in tolerogenic systems252. Therefore, this
data suggested that a tolerance mechanism is involved in the immunosuppressive effects
of oral M. avium in response to subsequent intradermal BCG vaccination.
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Figure 2.2 Analysis of cell phenotypes present in spleen and lung tissues after oral or intradermal
presensitization to M. avium. (A) Experimental design. Arrows indicate M. avium exposure. (B & C)
Number of CD4+, CD8+, CD11b+, and CD4+FoxP3+ cells in the spleens (B) and lungs (C) of mice; n=8 over
two separate experiments. (D) Number of M. avium CFU in the feces of mice presensitized to M. avium by
different exposure routes. A Mann-Whitney U test was used for comparison.*p<.05; **p<.01; ***p<.001
data shown with standard error of the mean (SEM).

To further examine the mechanism of EM immunosuppression of BCG
immunization, mice were chronically exposed to EM by two different exposure routes: oral
(O-MA) and intradermal (ID-MA). The same exposure and dosing regimen used earlier
was employed (Fig. 2.2A), with an additional group which received intradermal M. avium
exposure via superficial hip/flank injection, followed by ID-BCG. Immune cells were
assessed 6 weeks after initial M. avium exposure. Mice exposed to O-MA versus ID-MA
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prior to ID-BCG had similar splenic T cell (CD4+ and CD8+) and macrophage (CD11b+)
numbers. However, O-MA mice had 4-fold more splenic Treg (CD4+FoxP3+) cells (Fig.
2.2B). Lung tissue showed similar trends, with Treg levels 2-fold higher in the O-MA
group. In addition, pulmonary CD8+ cells were lower in the O-MA group; however, this
difference was not significant (Fig. 2.2C). These data suggest that oral M. avium exposure
generates a tolerogenic phenotype in mice and causes the immunosuppressive effects
observed in BCG immunized mice.
Mycobacterial colonization is dependent on route of exposure
We hypothesized if the immune system is not clearing EM from the GI tract due to an oral
tolerance mechanism, then M. avium should be present in the feces of the orally-exposed
mice259,260. Therefore, it was important to demonstrate bacterial colonization and survival
in the gut as an outcome of this oral tolerance model. To assess this, feces from each group
were pooled and plated for CFU determinations. No M. avium was detected in feces from
either treatment group on days 1 or 3 after the initial exposure (Fig. 2D). However, feces
from O-MA mice taken on the last day of chronic M. avium exposure (Day 21), showed
higher M. avium CFUs (3x103), compared to 8-fold fewer CFUs (3.5x102) in the feces of
ID-MA mice (Fig. 2.2D). Feces collected one week after the last M. avium exposure and
just prior to BCG immunization (Day 28) showed that orally administered M. avium
persists one week after the last exposure, implicating GI tract colonization by M. avium.
These data further support the hypothesis that chronic M. avium exposure establishes oral
tolerance to mycobacteria in the GI tract of hosts. Systemic M. avium numbers were
assessed after sacrifice in both spleen and lung, and the O-MA group had higher CFUs in
both tissues (SFig. 2.1).

53

Pulmonary versus intradermal BCG immunity
BCG in the lung is critical for the generation of tissue-resident immunity202,261. Therefore,
we assessed the ability of BCG to survive and migrate to the lung following intradermal
versus pulmonary immunization (Pul-BCG), using the previous experimental design (Fig.
2.3A). We observed that one week after immunization, both with and without prior M.
avium exposure, intradermal BCG immunization resulted in minimal BCG CFUs in the
lung tissue (Fig. 2.3B). Comparatively, pulmonary BCG immunization (O-MA+Pul-BCG)
resulted in a log increase in BCG CFUs in the lung with prior oral M. avium exposure.

Figure 2.3 Pulmonary versus intradermal BCG immunization. (A) Experimental design. Arrows
indicate M. avium exposure, (B) Number of BCG CFU in lungs of different immunization groups, n=6 over
two separate experiments. Post immunization IFN-γ production by BCG-stimulated T cells in the (C)
spleen, (D) Lung, and (E) BALF, n=6. A one-way ANOVA Kruskal-Wallis with Dunn’s multiple
comparison post-test was used to determine statistical significance. *p<.05; **p<.01; data shown with
standard error of the mean (SEM).
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These data suggest that low BCG levels in the lung following intradermal BCG vaccination
may limit induction of lung immunity136.
In addition to generating tissue resident immunity, various research suggests that
pulmonary immunization may be the only way to generate immunity in the
airways121,199,257. Concurrently, we inferred that systemic tolerance generated by M. avium
would not be present in the airway. To test this we compared IFN-γ production by T cells
in response to restimulation with heat-killed BCG in the M. avium-exposed, BCGimmunized groups (O-MA+ID-BCG, O-MA+Pul-BCG) compared to the intradermal-only
BCG group (ID-BCG) (Fig 2.3C). Compared to those from the ID-BCG group, splenic T
cells from the O-MA+ID-BCG and O-MA+Pul-BCG groups produced significantly less
IFN-γ. However, in both the lung and airway, only T cells from the O-MA+ID-BCG group
showed significantly reduced IFN-γ production compared to the ID-BCG control, whereas
O-MA+Pul-BCG had similar IFN- γ levels to that of the ID-BCG group (Fig 2.3D&E).
These data suggested that O-MA-mediated tolerance is not present in the airways.
Pulmonary BCG vaccination increases correlates of protection in the airway of EMexposed mice
To further evaluate the efficacy of pulmonary BCG vaccination in EM-exposed mice, we
measured known immunological correlates of protection against TB, including CD4+ T
helper cells, CD8+ cytotoxic T cells, CD44hiCD62Llo effector memory T cells, and
macrophages. C57BL/6 mice were chronically exposed to oral M. avium, rested for 1 week,
and then vaccinated with BCG by either the intradermal (O-MA+ID-BCG) or pulmonary
(O-MA+Pul-BCG) route (Fig. 2.4A). After 4 weeks, mice were euthanized and
bronchioalveolar lavage fluid (BALF), lung, and spleen were harvested to assess the
number of inflammatory cells and cytokine levels (Fig. 2.4B-E).
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Figure 2.4 Analysis of cellular correlates of protection in different immunization groups with and
without oral M. avium presensitization. (A) Experimental design. Arrows indicate M. avium exposure. (B)
CD4+ cells, (C) CD8+ cells, (D) CD44hiCD62lo memory cells, (E) CDllb+ (and CD11c+ for lung and BALF)
macrophages present in the spleen, lung, and BALF (airway) compartments, n=8 over 2 separate experiments.
A one-way ANOVA Kruskal-Wallis with Dunn’s multiple comparison post-test was used to determine
statistical significance. *p<.05; data shown with standard error of the mean (SEM).

Lung and spleen homogenates showed minimal differences in immune cell
numbers (CD4+, CD8+, CD44hiCD62Llo memory, and macrophages) regardless of
immunization route (Fig. 2.4; Spleen & Lung panels). Interestingly, both the lung and
spleen tissues showed diminished CD4+ and CD8+ T cells in the O-MA+ID-BCG group
compared to the O-MA+Pul-BCG; however, these differences were not significant.
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Conversely, the airway (BALF panel) of the pulmonary-vaccinated groups had
significantly higher immune cell numbers compared to other groups, and importantly, OMA exposure did not diminish the Pul-BCG-generated immune response in this
compartment (Fig. 2.4; BALF panels). Together with the rescued IFN-γ levels associated
with O-MA+Pul-BCG (Fig. 2.3D&E), these data suggest that pulmonary BCG vaccination
generates better correlates of protection than intradermal BCG in an M. avium-exposed
host.
Pulmonary BCG vaccination protects EM-exposed mice against Mtb
The ultimate measure of any vaccine’s efficacy is pathogen challenge. Therefore, to test
whether pulmonary BCG could protect EM-exposed mice against Mtb challenge, C57BL/6
mice were exposed chronically to oral M. avium as performed before (Fig. 2.5A). Mice
were rested for 1 week and then vaccinated with BCG by either the intradermal or

Figure 2.5 Mtb aerosol challenge studies. (A) Experimental design. Mice immunized with BCG by the
intradermal and pulmonary route, with and without presensitization with oral M. avium, were challenged with
Mtb. (B) Number of Mtb CFU in lungs of different immunization groups, n=4-15 per group. A one-way
ANOVA Kruskal-Wallis with Dunn’s multiple comparison post-test was used to determine statistical
significance. *p<.05; data shown with standard error of the mean (SEM).
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pulmonary route. After 4 weeks, mice were challenged with aerosolized Mtb. Mice were
rested for 5 weeks before euthanasia, and tissues were assessed for Mtb burden by plating
for CFUs.
An M. avium only group was not included in the challenge study, as it has been
shown previously that M. avium does not offer protection against aerosol Mtb
challenge136,138. Unvaccinated Mtb-challenged (No trt) mouse controls showed marked
pulmonary infection, with greater than 106 Mtb CFUs present in the lung 5 weeks after
aerosol infection (Fig. 5B), whereas ID-BCG and Pul-BCG immunization significantly
diminished TB burden. In agreement with previous studies136, O-MA+ID-BCG mice
showed Mtb bacterial numbers equal to that of the unvaccinated controls, confirming that
M. avium exposure renders intradermal BCG ineffective136–140. Importantly, Pul-BCG and
O-MA+Pul-BCG mice showed similar and significant Mtb clearance, compared to No Trt
and O-MA+ID-BCG. This confirms that pulmonary BCG vaccination can circumvent the
immune suppression caused by previous chronic M. avium exposure (Fig. 2.5B).
Changes in lung tissue and mouse weight five weeks after Mtb infection were used
to assess morbidity. There was no difference in total lung weight among groups (data not
shown); however, O-MA+ID-BCG mice showed decreased weight gain after Mtb infection
compared to the immunization control mice (ID-BCG), suggesting increased morbidity
following prior M. avium exposure (SFig. 2.2).
To assess differences in tissue inflammation between M. avium-exposed and BCGimmunized mice following Mtb challenge, lungs and spleens were excised and stained with
hematoxylin and eosin (Fig. 2.6). Lungs of untreated animals (No Trt) showed considerable
pathology, with granulomatous lesions occupying an average of 11% of the area of lung
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sections (Fig. 2.6A&B). Pul-BCG and ID-BCG groups showed minimal inflammation,
with inflammatory infiltrates making up 4% and 0.03% of the lung area, respectively. OMA+ID-BCG and O-MA+Pul-BCG groups also had minimal inflammation; with lesions

Figure 2.6 Histopathological analysis of lung and spleen tissue after Mtb aerosol challenge in
different immunization groups, with and without oral M. avium presensitization. (A) H&E-stained
lung sections were assessed for granulomatous inflammation, arrows indicate foci of granulomatous
inflammation. (B) Higher magnification (5X) of lung sections. (C) Spleens were assessed for lymphoid
hyperplasia, the arrow indicates an area of white pulp used to assess lymphoid hyperplasia. n=2 mice per
group, data shown is from one experiment and representative of three independent experiments.

occupying less than 2% of the area of lung sections for each group. These data suggest
that Pul-BCG immunization causes more inflammation in the lung than ID-BCG
immunization; however, this difference is minimal and is likely due to the presence of BCG
in the lung and not due to Mtb infection based on lung CFUs (Fig. 2.5B). Lymphoid
hyperplasia in the spleen, assessed by quantifying the relative area of the white pulp in each
spleen section, was used as an indirect measure of the systemic immune response to Mtb
challenge (Fig. 2.6B). In No Trt mice, the white pulp occupied an average of 29% of the
spleen area. Both BCG-vaccinated groups had higher percentages of white pulp, with 44%
for ID-BCG and 31% for Pul-BCG groups. O-MA+ID-BCG animals had a white pulp area
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of 30%, a reduction of 14% compared to the ID-BCG group. The most prominent lymphoid
hyperplasia was seen in the O-MA+Pul-BCG group, with a total white pulp area of 47%.
Taken together, these findings suggest that pulmonary vaccination is better than
intradermal vaccination at stimulating a systemic immune response in M. avium-exposed
mice.

Discussion
The BCG vaccine is given by the intradermal route in over 150 countries worldwide262;
however, its efficacy is impaired in areas where EM are endemic128,135. Prior EM exposure
has been shown to be detrimental to BCG protective efficacy in mice136,138–140,263. Two
mechanisms have been proposed for the failure of BCG due to EM exposure, the blocking
and the masking hypotheses142, which propose that BCG replication is blocked or BCG
immunity is masked by EM, respectively. Here we show evidence for an alternate
mechanistic hypothesis, BCG vaccine interference via oral tolerance, which may
encompass both the blocking and masking hypotheses142. Importantly, we sensitized mice
via the oral route to mimic human ingestion of EM and without antibiotic clearance,
whereas early studies used parenteral exposure with antibiotic clearance of the EM before
vaccination136,137. To our knowledge, this is the first study to demonstrate oral tolerance as
a mechanism of BCG vaccine failure.
We used a mouse model to investigate the mechanism of EM interference by
exposing mice to M. avium (a common EM) via the oral route to mimic human exposure
via food and water sources139,140. Mice were then vaccinated intradermally with BCG. The
immune response of mice, based on IFN- production by T cells following ex vivo BCG
restimulation, was significantly decreased in mice exposed to M. avium prior to intradermal
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vaccination (Fig. 2.1C). This corroborates previous findings that M. avium exposure
impairs the immune response to BCG136,138–140,263. Interestingly, the masking hypothesis
states that a naïve host produces a lower initial proinflammatory response to EM
presensitization than they would to BCG immunization. After EM presensitization,
individuals vaccinated with BCG cannot produce a proinflammatory response to BCG that
ever surpasses the initial proinflammatory response to EM; thus, the immune response to
EM masks the subsequent immune response generated against BCG141,142. Although our
data, as well as those of others, initially appeared to support the masking hypothesis, we
further explored the mechanism of BCG vaccine interference141,143.
We examined the cross-reactivity of T lymphocytes to M. avium and BCG by taking
T cells from ID-BCG or O-MA exposed mice and restimulating with either antigen ex vivo.
We observed identical IFN-γ responses in tissue-specific T lymphocyte populations from
both exposure groups (Fig. 2.1B). This suggests that the immune cells cannot distinguish
between the live BCG vaccine and M. avium, a typical EM strain. Therefore, the EM
immune response does not “mask” the BCG-specific response, but rather this
immunosuppression is a consequence of cross-reactivity between the two mycobacterial
species, wherein the host immune system cannot distinguish between M. avium and M.
bovis BCG.
To determine if the immunosuppressive effect of M. avium depended on the route
of M. avium exposure, mice were administered M. avium chronically by either the oral or
by the intradermal route. Mice exposed to M. avium by the oral route, but not by the
intradermal route, had elevated Treg cells in the spleen (Fig. 2.2B) and increased IL-10
secretion by both splenic and lung T cells in response to BCG restimulation (Fig. 2.1D).
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Treg cells and IL-10 are both mediators of oral tolerance252,254. This data is also supported
by some epidemiological data examining patients with EM infections. These individuals
present with increased T regulatory numbers, along with the associated cytokines264. This,
coupled with M. avium colonization of the GI tract in mice exposed orally (Fig. 2.2D),
suggests that the immunosuppressive effects of EM are closely linked to the oral route of
exposure.
Another mechanism for BCG vaccine interference by EM is described by the
blocking hypothesis136. This hypothesis suggests that BCG is eliminated in hosts after
vaccination due to prior EM immunity, and a BCG-specific immune response is never
initiated. However, early animal experiments supporting this hypothesis did not utilize oral
EM administration, the most common route of human exposure, thus oral tolerance was
not observed136. Our study shows that the immunosuppression against BCG vaccination
associated with M. avium is linked to the oral route of exposure. Only oral M. avium
exposure increased splenic and lung T regulatory cells (Fig 2.2B). Furthermore, with
respect to the blocking hypothesis, we show that BCG migrates minimally to the lung after
intradermal immunization, regardless of prior EM exposure (Fig 2.3A). Thus a robust local
immune response to BCG is not generated in the lung. However, mice vaccinated by the
pulmonary route had more BCG in the lung one week after immunization (6 weeks after
initial M. avium exposure) and thus produced a Th1 immune response. These data support
our hypothesis that EM immunosuppression is an oral tolerance mechanism, and that the
route of EM exposure and BCG immunization are both important (Fig 2.7).
Our next step was to investigate whether EM-driven immunosuppression can be
overcome by delivering the BCG vaccine by the pulmonary route. Horvath and colleagues
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demonstrated that the pulmonary airway is an isolated immune compartment which can
only be effectively immunized against TB via the pulmonary route257. According to these
authors, parenteral vaccination is sufficient to generate immune cells in the systemic
circulation and in the lung parenchyma; however, only intranasal immunization generates

Figure 2.7 Pulmonary BCG immunization is effective at protecting against Mtb in EM-exposed hosts
chronic oral exposure to EM generates systemic tolerance against mycobacteria. This tolerance
generates poor immunity in a subsequent intradermal BCG vaccination scenario, and could lead to variable
vaccine efficacy. However, because systemic tolerance is not present in the airways of hosts, pulmonary
immunization generates robust immunity and is protective against Mtb challenge.

an adaptive immune response in the lung airway compartment. We hypothesized that the
airway would be immunologically naïve to EM-generated systemic tolerance induced via
a gut-mucosa-specific mechanism. As expected, mice vaccinated with BCG by the
pulmonary route after oral M. avium exposure had significantly higher Th1 responses in
the airway, as demonstrated by the large number of T-lymphocytes (both helper and
cytotoxic), effector memory cells, and macrophages present in BALF (Fig. 4; BALF
panel), compared to M. avium-exposed mice subsequently vaccinated intradermally with
BCG. Most importantly, we showed that oral EM exposure impairs the efficacy of
63

intradermal, but not pulmonary, BCG vaccination against subsequent aerosol Mtb
challenge (Fig. 2.5B). These results show that pulmonary BCG immunization is effective
at protecting against Mtb, even in EM-exposed individuals.
To determine the broader implications of these studies, future experiments should
test the ability of multiple strains of orally administered EM to interfere with BCG efficacy.
In addition, many of the details of this tolerance mechanism still remain unknown. Does
oral EM exposure after vaccination still result in tolerance? Is this tolerance cross-specific
to Mtb as well? Furthermore, how does pulmonary EM exposure affect the airway? EM
exposure by the pulmonary route could prove technically challenging to study due to
mucociliary clearance from the airways and subsequent ingestion of the EM. These
questions must be answered to completely understand the mechanisms behind the failures
and successes of prospective TB vaccines currently in clinical trials.
This work helps us to understand the limitations of the current BCG vaccine and
the potential for failure of any new vaccine administered by the parenteral route165. If oral
tolerance interferes with the intradermal BCG vaccine in humans, then it has major
implications for vaccines against TB and other infectious diseases. Since EM are
ubiquitous soil and water residents, little can be done to avoid human exposure. Moreover,
the effects of oral tolerance are not tissue specific. Tolerance is generated in the GI tract,
and tolerogenic T cells migrate throughout the body via the circulation252,254. This may
result in the failure of any new intradermal TB vaccine that uses mycobacterial antigens.
We have demonstrated that pulmonary immunization will circumvent EM-generated
tolerance and provide protective immunity against Mtb. Importantly, this immunity is
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evident in the airways, the tissue compartment where the host first encounters this
important human pathogen.

Methods
Animals
Female, pathogen-free, 6-12 week old C57BL/6 mice were purchased from Jackson
Laboratory (Bar Harbor, ME). Animals were kept in cages with laminar flow safety
enclosures and housed by groups. Mice were acclimatized for at least one week in a
climate-controlled room on a 12-hour light-dark cycle and were fed ad libitum prior to
starting the experiments. All experiments were approved by the UNM HSC IACUC
(Protocol #12-100817-HSC) and conformed to the Guide for the Care and Use of
Laboratory Animals 265.
Mycobacteria
Mycobacterium avium (ATCC 700898), Mycobacterium bovis BCG Pasteur (ATCC
35734), and Mycobacterium tuberculosis strain H37Rv (ATCC 27294) were grown in
Middlebrook 7H9 broth (Fluka analytical, Buchs, Switzerland) supplemented with 0.05%
glycerol (Fisher Scientific, Waltham, MA) and 10% albumin-dextrose-catalase (BD
diagnostic Systems, Franklin Lakes, NJ) at 37°C to mid-log phase of growth. M. avium
was chosen as the experimental EM species because of its use in earlier literature and
because of its ability to cause persistent infections in humans and mice

136,138,140

. In

preparation for oral gavage, intradermal exposure or vaccination, and aerosol
administration- M. avium, BCG, and Mtb were pelleted at 1800xg and resuspended in
saline. Harvested tissue homogenates were plated on Middlebrook 7H10 agar (Fluka
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analytical, Buchs, Switzerland) supplemented with 0.05% glycerol (Fisher Scientific) and
10% oleic acid-albumin-dextrose-catalase broth for 14-28 days at 37oC. Mycobacterial
strains were differentiated by supplementing agar with clarithromycin (Sigma Aldrich, St.
Louis, MO, 2µg/mL) and/or 2-thiophenecarboxylic acid hydrazide (TCH) (Sigma Aldrich,
2µg/mL) to exclude M. avium or BCG, respectively. M. avium in feces was collected (by
group) and 75mg was suspended in 1mL before plating for analysis on plates containing
2-thiophenecarboxylic acid hydrazide to exclude BCG. Tissues for Mtb enumeration were
plated with both clarithromyocin and TCH to block both BCG and M. avium growth.
Sensitization with EM
Mice were exposed to a 50μL dose of M. avium orally (2 x 106 CFU) by gavaging with an
18-gauge blunted needle (O-M.A.) (Fine Science Tools, Foster City, CA) or by intradermal
injection (ID-M.A.) on the flank (2 x 106 CFU). M. avium exposure was repeated two times
a week for four weeks (total 8 exposures). Dosing CFUs were taken from earlier literature,
and timelines were created to mimic chronic oral exposure to EM by humans 136,138,263.
Vaccination
The dosing of BCG followed earlier literature 136 and the intradermal route was chosen as
this is the current route of immunization in humans. Mice were vaccinated one week after
the last presensitization with M. avium. A single 50μL dose of 5x107 CFU BCG was given
by the intradermal route (ID-BCG) on the flank or by endotracheal aerosolized (Pul-BCG)
delivery using a MicroSprayer® Aerosolizer (Penn Century, Wyndmoor, PA) while mice
were anesthetized with constant 3% isoflurane. Mice were sacrificed either one week (six
weeks after the first M. avium exposure) or four weeks (nine weeks after the first M. avium
exposure) after BCG immunization.
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Aerosol TB infection
Mice were infected with a low-dose aerosol Mtb (200 CFU) four weeks after vaccination
via endotracheal aerosolization using the Penn Century MicroSprayer® Aerosolizer while
anesthetized with ketamine and xylazine (9+90mg/kg). Mice were sacrificed 5 weeks after
aerosol infection and tissues were plated for M.tb growth. Mice which showed no infection
(by plating) were not included.
Tissue preparation
Mice were sacrificed 1 week after vaccination (oral tolerance experiments) or 5 weeks after
vaccination (correlates of protection experiments). Tissue samples were collected and
prepared as described below.
Splenic lymphocytes
Isolated spleens were placed in a tube containing ice cold Dulbecco’s Phosphate Buffered
Saline (DPBS) (Gibco, UK) supplemented with 2.5% fetal bovine serum (FBS) (Life
Technologies, Carlsbad, CA). Spleens were dissociated using mouse spleen dissociation
protocol 1 on a gentleMACS™ tissue dissociator (Miltenyi Biotec Ltd., Bergisch
Gladbach, Germany). Dissociated spleens were pushed through 40μm mesh cell strainers
(Fisher Scientific, Fisher Scientific) and pelleted. Pellets were resuspended in 5mL of
MACS Red Blood Cell Lysis Solution (1X) (Miltenyi Biotec Ltd.) and incubated for 10
minutes at room temperature. Splenic cells were again pelleted and resuspended in 5mL of
Dulbecco’s Modified Eagle Medium (DMEM) (Gibco).
Lung tissue
Lung tissue was isolated, and placed in a tube containing ice cold dissociation buffer
consisting of DPBS supplemented with 2.5% FBS, 40U/mL DNAse 1 (Sigma Aldrich),
and 150U/mL Collagenase 1 (Sigma Aldrich). Lungs were partially dissociated using the
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mouse lung dissociator program 1 on a gentleMACS™ tissue dissociator. Lung tissue was
then incubated in the dissociation buffer for 1 hour at 37°C on a shaker. After incubation
lung tissue was further dissociated on the gentleMACS™ tissue dissociator using mouse
lung dissociation program 2. Dissociated lungs were then pushed through 40μm mesh cell
strainer and the cells were pelleted. Pellets were resuspended in 5mL of MACS Red Blood
Cell Lysis Solution (1X) and incubated for 10 minutes at room temperature. Lung cells
were again pelleted and resuspended in 5mL of DMEM.
Immunophenotyping via flow cytometry
1x106 cells per tissue preparation were stained for flow cytometry according to the antibody
manufacturer’s instructions (eBiosciences, San Diego, CA). Briefly, anti-CD4 PerCPCy5.5, CD8 APC-eFluor® 780, CD11b PE-Cyanine7, CD11c eFluor® 450, CD3 APC,
CD44 FITC, CD62L eFluor® 605NC, and anti-FoxP3 PE (after fixation and
permeabilization) antibodies were incubated with cells for 30 minutes in the dark at 4°C
and cells were then fixed with 4% paraformaldehyde. Cells were resuspended in FACS
buffer and samples were analyzed on the LSRFortessa Flow Cytometer (Becton Dickinson,
Franklin Lakes, NJ). Lymphocytes were gated based on their forward- and side-scatter
profiles and the presence of CD3, and then sub-gated on CD4 (minus CD4+FoxP3+ cells),
CD8, and CD44hiCD62Llo. Macrophages were gated on their forward- and side-scatter
profiles and the presence of CD11b, with sub-gating in lung homogenates on CD11c for
alveolar macrophages.
T-cell restimulation and ELISA
Lymphocyte preparations were counted and 106 cells plated per well in a 24-well round
bottomed plate with DMEM media supplemented with 10% FBS. Heat killed BCG was

68

added to the cells at a multiplicity of infection (MOI) of 5. Cells were incubated at 37°C
for 48 hours in 5% CO2. Cell supernatants were collected and assessed for cytokines using
either Milliplex bead based cytokine kits (EMD Millipore, Billerica, MA) or using the
Ready-Set-Go ELISA (eBiosciences). ELISAs were read on a Tecan Microplate reader
(Mannedorf, Switzerland) and Milliplex assays were measured on a Bio-Rad Bio-Plex 200
system (Bio-rad, Hercules, CA).
Histopathology
Mouse lungs and spleens were removed en bloc. Lungs were inflated with 10%
paraformaldehyde and both lung and spleen were submerged in 10% paraformaldehyde for
1 week. Lungs and spleen were embedded in paraffin blocks, sectioned at 4-5µm and
stained with hematoxylin and eosin (H&E). Histopathology was performed by a boardcertified veterinary pathologist (DFK). H&E-stained slides were digitized for
morphometric analysis using an Aperio CS2 slide scanner (Leica, Buffalo Grove, IL) and
analyzed using associated morphometry algorithms. Granulomatous inflammation in the
lung was determined by manually outlining all foci of inflammation and determining the
total area of inflammation as a percentage of the total area of the lung. The area of white
pulp in a longitudinal spleen section was obtained by manually outlining all lymphoid
aggregates and determining the total area of the white pulp as a percentage of the total area
of the spleen.
Statistical methods
All statistical analysis was performed using Graphpad Prism statistical software (GraphPad
Software, San Diego, CA). The Mann Whitney test for non-parametric data of two groups,
and the one-way ANOVA Kruskal-Wallis with Dunn’s multiple comparison post-test was
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used for multiple comparisons of non-parametric data. Statistical significance was reported
as *, P < .05; **, P < .01; ***, P < .001; ****, P < .0001.
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Supplemental figures

Supplemental 2.1 M. avium CFUs in lung and spleen after different routes of presensitization. M.
avium in the lung and spleen of mice presensitized by either the oral or intradermal route, n=8.

Supplemental 2.2 Animal weights after infection. Weight gain after infection; n=8. A one-way ANOVA
Kruskal-Wallis with Dunn’s multiple comparison post-test was used to determine statistical significance.
*p<.05; data shown with standard error of the mean (SEM).
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Abstract
The current vaccine against Mycobacterium tuberculosis (Mtb), Bacille Calmette-Guérin
(BCG), has a highly variable efficacy rate of 0-80% in terms of protecting against infection.
Recently, our laboratory has shown that some of this variability may be related to the route
by which BCG is currently administered. BCG is a live, attenuated form of Mycobacterium
bovis given by the intradermal route. Concurrently, our laboratory and others have shown
that administering BCG by the pulmonary route greatly increases its efficacy. However,
vaccine losses from exposure to high and freezing temperatures during storage and
transport remain a significant obstacle to BCG and other live vaccines. In this study, we
aimed to create a stable BCG dry powder suitable for pulmonary delivery using a factorial
design

to

evaluate the

excipients

L-leucine,

bovine

serum

albumin,

polyvinylpyrrolidone, mannitol, and trehalose at different concentration ratios. Spraydried powders were characterized based on size, yield, water retention, water uptake, and
glass transition temperature. Three optimal dry powder carriers were selected based on
stability and flow characteristics, and these were spray-dried with live BCG to yield dry
powders with an aerodynamic diameter in the range of 1-5 µm. BCG dry powders will be
assessed for viability, shelf-life, antigenicity, and lung dispersion in mice. This spray-dried
live BCG will be highly stable and antigenic, providing the ideal inhalable vaccine delivery
platform against tuberculosis.

Introduction
Vaccines are the most powerful and effective achievement of modern medicine7,266–268.
Starting with Jenner’s small pox vaccine in 1796, the availability of immunizations has
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radically diminished cases of smallpox, polio, measles, rubella, yellow fever, mumps, and
influenza266–268. Today, there are more than 70 vaccines licensed for use against different
microbes and 100 million infants are immunized each year, saving approximately 3 million
lives annually266,269. Despite these successes, the World Health Organization (WHO)
estimates that more than 1.5 million children die from vaccine preventable diseases each
year270,271. Many of these deaths occur in resource-poor countries, where vaccine programs
are in place but cold-chain infrastructure is insufficient272–274.
The exposure of vaccines to improper storage conditions and temperatures can
result in vaccine inefficacy and instability, which consequently leads to limited coverage
of immunization programs275,276. Different studies have shown that between 14-50% of
vaccines are exposed to excessive heat or cold temperatures during storage and transport,
leading to partial or complete damage in vaccine potency269,272,277,278. Considerable effort
and financial support has been given to assessing and optimizing weak points in the cold
chain storage infrastructure, such that cold chain accounts for nearly 80% of the total cost
of vaccination programs226.
Bacille Calmette-Guérin (BCG) is the only licensed vaccine against tuberculosis
and is intradermally administered in more than 150 countries worldwide262. Despite
widespread use, the vaccine is ineffective at protecting against tuberculosis, with variable
efficacy rates of 0-80% depending on geographical location142,144. Recently, our laboratory
has shown that administering BCG by the pulmonary route may eliminate the variable
efficacy193. Concurrently, other groups have shown that dry powder vaccines have
increased thermostability and can be formulated for pulmonary delivery123,232,237,207,279–281.
Vaccines in the dry powder state can be protected from degradation by the addition of
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protective excipients. Dry forms of vaccines are able to withstand higher temperature and
thus

minimize

the

cold

chain

requirements

during

storage,

transport,

and

administration225,239.
Here we show the development and optimization, using a factorial design involving
five excipients, of a thermostable BCG dry powder vaccine. Furthermore, we characterize
the live vaccine powder for its shelf-life at different storage temperature and humidity
conditions and its aerodynamic properties suitable for pulmonary administration.

Results
Factorial design of excipients
To optimize the BCG dry powder stability, a factorial design of excipients was performed
and desired product parameters were assessed using Design Expert® software. Leucine
was chosen as the bulk excipient (70-90%) because of its flow characteristics and its ability
to decrease bacterial osmotic stress shown in previous BCG studies244 (Table 3.1). Dmannitol was added (10-20%) for its low hygroscopicity which has been shown to plateau
in effect at 20%282. Trehalose and Polyvinylpyrrolidone (PVP) were assessed at ratios of
0-5% to raise the glass transition temperature (Tg) of the powder and prevent crystallization
of the bacteria. Lastly, bovine serum albumen (BSA) was added at 0-5% to stabilize
proteins and prevent recrystallization of excipients.
A quadratic mixture design was employed using coordinate exchange to assess the
excipient mixtures for the following measurable characteristics: yield, size, residual
moisture content after drying, moisture uptake, and Tg. These powder characteristics
inform the stability of the powder mixture that will ultimately encapsulate BCG, which is
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Figure 3.1 Effect of changing excipient ratios on powder physical properties. A) Yield, B) Size, C)
Residual moisture after spray drying, D) Moisture uptake, and E) Tg as shown by Piepel trace plot. For
each trace plot: A-Mannitol, B-Leucine, C-PVP, D-BSA, E-Trehalose; ANOVA statistical analysis with
p values shown.

a live vaccine. Ideally, we wanted an excipient mixture that will allow us to formulate
powders in the 1-3 µm range. Powders should retain minimal residual moisture to prevent
degradation and agglomeration. Lastly, the powders had to have low hygroscopy (moisture
uptake ability) to prevent degradation of the excipients and ultimately bacterial death, and
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similarly had to have high Tg so that the excipients would not crystallize and damage the
bacterial cell wall.

Figure 3.2. Overall interaction of excipients and responses. Blue responses are favorable and red
responses are unfavorable with respect to optimized input parameters. White responses show no effect.

The factorial design generated a total of 25 runs which were spray-dried,
characterized, and recorded. Excipient mixture did not affect yield (Fig. 3.1A). Powder
size after spray drying was significantly affected by the various excipient concentrations,
with leucine and BSA influencing the size the most (Fig. 3.1B). Residual moisture content
in the spray-dried powders was directly proportional to PVP and BSA, and inversely
proportional to L-leucine concentration (Fig. 3.1C). Uptake of environmental moisture
appears to be mainly mediated by L-leucine (Fig. 3.1D). Interestingly, higher BSA
concentration in the excipient mixture was moisture protective under humid conditions
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(p=.0513). Lastly, increasing PVP, trehalose, and BSA concentrations in the spray drying
excipient mixture produced dry powders having an overall high Tg (Fig. 3.1E).
Table 3.1 Optimal excipient mixtures

Number Excipient Formulation

Desirability

Leucine

Mannitol

PVP

BSA

Trehalose

*1

75.2

10.0

5.0

4.8

5.0

0.902-0.976

*2

73.3

11.7

5.0

5.0

5.0

0.890-0.978

*3

71.0

14.0

5.0

5.0

5.0

0.867-0.980

4

68.9

17.6

4.2

4.2

5.0

0.793-0.885

5

65.4

19.8

4.9

4.8

5.0

0.779-0.886

6

75.0

14.0

3.0

3.0

5.0

0.756-0.829

7

78.0

12.0

1.0

4.0

5.0

0.728-0.815

8

75.5

14.2

2.6

2.7

5.0

0.719-0.787

9

76.1

14.4

2.2

2.2

5.0

0.665-0.727

* Chosen excipient mixtures

The Design Expert software did not generate an optimal formulation when all the
selected parameters were taken into account (Fig. 3.2). Therefore, yield and residual
moisture content after spray drying were removed as response elements in the optimization
equation. Yield was not significantly affected by excipient concentration and all residual
moisture measurements were close to optimal ranges. Therefore, the removal of these
responses was deemed acceptable. With optimal ranges of the three remaining response
elements (size, moisture uptake, and Tg), Design Expert generated 9 optimized excipient
mixtures (Table 3.1). The first three excipient formulations were chosen to spray dry with
BCG.
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Optimized BCG dry powder characterization
BCG was spray-dried, with the three excipient mixtures chosen by the design as done
previously. A blank dry powder (without BCG) was also made for each of the three BCG
powders. Additionally, a batch of dead BCG in excipient mixture 3 was also spray-dried.
Spray drying the optimized blank formulations resulted in an average particle size range of
Dx(50)= 2.02±2.14 μm, with mixture 2 having the largest size (Table 3.2). The dead BCG
powder was sized as well to assess how the incorporation of a micron-sized bacteria would
change the size of the powders. This difference in size was minimal. According to these
sizing values, the percent inhalable particles (particles between 1-5μm; fine particle
fraction) was in the range of 80% of the total particles.
Table 3.2 Yields and sizes of optimized formulations

Formulation

Yield

Dx (10)

Dx (50)

Dx (90)

Tg

Powder 1

58.41

0.84 ± 0.00

2.06 ± 0.01

4.71 ± 0.06

38.41

Powder 2

58.48

0.85 ± 0.01

2.14 ± 0.01

4.93 ± 0.02

34.99

Powder 3

55.37

0.75 ± 0.00

2.02 ± 0.00

4.98 ± 0.05

32.01

Leucine

60.99

1.90 ± 0.01

5.29 ± 0.04

10.30 ± 0.10

--

53.35

0.99 ± 0.01

2.14 ± 0.06

4.66 ± 0.19

--

powder
Dead BCG
powder

Glass transition temperatures were obtained for each of the optimized blank
formulations. Powder 1 gave the highest Tg with a value of 38.41°C (Table 3.2). Powder
2 gave the second highest Tg with a value of 34.99°C. Powder 3 had the lowest Tg, 32.01°C,
but overall the difference was minimal. To confirm that the powders were amorphous,
XRD was used to assess the crystallinity of the mixtures (Fig 3.3). As expected, powder 3
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was the most crystalline, and powders 1 and 2 were similar in crystallinity, with nearly
identical peak intensities.

Figure 3.3 XRD crystallography graphs of optimized formulations. Powder 1 is displayed on bottom
in blue, powder 2 is in the middle in green, and powder 3 is on the top in red. Increasing intensity counts
on the y-axis show structure crystallinity.

Residual moisture and moisture uptake (hygroscopicity) in the dry powders were
assessed as done previously (Table 3.3). As expected, each optimized dry powder
formulation performed better than leucine powder alone, with the exception of powder 3
for residual moisture. As predicted by the powder desirability in Table 3.1, powder 1 had
the lowest residual moisture and the least moisture uptake, followed by powder 2, and
powder 3.
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Table 3.3 Residual moisture and moisture uptake.

Formulation

% Residual Moisture

% Moisture Uptake

Powder 1

25

70

Powder 2

29

75

Powder 3

53

86

Leucine powder

49

103

Powders were assessed for morphology using SEM (Fig 3.4A&B). Blank
formulations were visualized first, and powder containing dead bacteria was comparatively
assessed for any differences in morphology. All blank optimized powders and dead BCG
powder were spherical and appeared somewhat porous with uneven surfaces. Importantly,
there were no obvious differences in surface morphology between the blank powders and
the powder containing BCG. TEM was used to observe whether BCG lost its integrity after
spray drying. For TEM studies optimized powders were compared to leucine powder after
re-suspension in paraformaldehyde (Fig 3.4C&D). Intact BCG was observed in all
samples, without any visible damage to the cell wall. No discernable differences were
observed between BCG in the optimized powders compared to the leucine powder.
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Figure 3.4 SEM and TEM visualizations of dry powder particles. (A&B) SEM at 10,000x
magnification, A) powder with dead BCG, and B) powder 2; (C&D) TEM at 3000x magnification, C )
Mixture 2 with BCG, and D) Leucine with BCG.

All of the powders were assessed for bacterial viability following spray drying to
determine losses due to the heat-intensive procedure (Fig. 3.5). Again, L-leucine
containing BCG was used as a control sample as it is the current standard BCG dry powder
formulation244. All powders (1, 2, and 3) showed minimal losses after spray drying (less
than half a log loss) and superior viability after spray drying compared to the Leucine
control which decreased by more than a log.
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Figure 3.5 BCG loss after spray drying. Gray portion of bar shows loss in BCG viability immediately
after the spray drying process compared to the pre-spray drying CFUs (whole bar).

Stability of BCG dry powders
The three optimized BCG powders, as well as the BCG-Leucine control powder, were
stored at the following conditions: 4°C, 25°C (40% RH), 25°C (60% RH), and 40°C (75%
RH). They were stored in a packaging system previously developed in our laboratory which
prevents moisture uptake and reactive oxygen species (ROS) generation. In addition,
powders were assessed without protection from packaging at 4°C, 25°C, and 40°C (75%
RH). BCG powders stored in the above conditions were compared to control BCG
suspensions stored at 4°C. Lastly, the effect of freezing during storage and transportation
of a vaccine product was assessed by measuring the BCG viability after three freeze-thaws
for the BCG powders. Different experimental conditions and their associated timelines are
summarized in Table 3.3 in the methods section.
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These long-term stability studies are ongoing, with 4 weeks of viability data
available for samples with protective packaging (P BCG) (Fig. 3.6) and 2-4 weeks
available for samples without packaging (NP BCG) (Fig. 3.7). However some differences
are already evident. After 1 month of storage, P BCG powders are stable at 4 ºC, 25ºC/RH
40 & 60%, and 40ºC/RH 75% (Fig.3.6). However, BCG encapsulated in leucine powders
appears to lose viability at higher humidity and temperatures, with viability losses ranging
from 1-2 logs (Fig. 3.7).

Figure 3.6 Stability of package protected dry powders. Viability of dry powder BCG stored in
protected packaging at A) 4ºC, B) 25ºC at 40% RH, C) 25ºC at 60% RH, and D) 40ºC.

Powders without protection showed less viability than those with protective
packaging. After two weeks of storage, optimized powders showed stability at 4ºC, without
any loss in BCG CFUs (Fig. 3.7A). However, viability was diminished at 25ºC (Fig. 3.7B)
by 2 log and nearly undetectable at 40ºC/75RH (Fig. 3.7C) at the two week timepoint.
Importantly, powders showed no loss in viability after two freeze-thaws (Fig. 3.7D). As
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expected, optimized powders performed better than leucine powder at stabilizing BCG at
every temperature. Interestingly, solutions showed no loss at 4ºC, except in the leucine
solution (Fig. 3.7E).

Figure 3.7 Stability of unprotected dry powders. Viability of dry powder BCG stored in without
protective packaging (A-D) at A) 4ºC, B) 25ºC at 40% RH, C) 25ºC at 60% RH, D) 40ºC/ 75RH; and E)
Solutions at 4 ºC.

Discussion
The temperature stability of a live vaccines is critical to maintain its potency. Currently
cold chain is required for most vaccines277. In spite of the cold chain, many vaccines are
adversely affected during transport and storage every year due to both high and freezing
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temperatures. Dry powder vaccines have considerable advantages compared to liquid
preparations since stabilizing excipients can be added to dry powder formulations to protect
bacteria at different environmental conditions123,232,237,207,280,283,211.
Initial studies used L-leucine as the excipient to formulate a BCG dry powder123,244.
The authors reasoned that leucine would eliminate the osmotic pressure exerted on the
bacterial membrane by cryoprotectants and salts that are used in the freeze-drying process
that is currently employed to make the BCG vaccine. In addition, leucine provides better
flow characteristics to the dry powders. The authors also showed BCG viability in leucine
powders for 4 months at 25ºC. However, since these initial findings, research describing
stability of vaccines in dry powders has increased beyond 4 months and 25ºC237,207.
Using other dry powder vaccine literature as a starting point, we used a factorial design of
excipients to optimize a BCG dry powder formulation for stability at elevated temperature
and humidity conditions. We selected excipients that had shown previously to enhance
flow properties, maintain amorphous structure, and decrease hygroscopicity. We
hypothesized that these characteristics would be critical to maintain bacterial and powder
stability.
Our design looked at five different output parameters in order to optimize the
excipient ratio; (1) yield, (2) residual moisture, (3) moisture uptake, (4) size, and (5) Tg.
We inferred that these powder characteristics would have the greatest effect on maintaining
the viability of BCG during storage. Interestingly, spray-dried leucine powders had the
most variable effect out of all the 5 excipients considered in our factorial design. While
leucine powders had higher yield after spray drying, its inclusion negatively impacted size,
moisture uptake, and Tg (Fig. 3.1). In agreement with previous work, we found that
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mannitol lowered the Tg of the spray-dried powders (Fig. 3.1E). This was concerning
because low Tg could negatively affect the bacterial viability, if these powders crystallize
during storage. However, PVP and trehalose in the powder mixture increased the Tg, thus
negating some of mannitol’s Tg-lowering effect (Fig. 3.1E).
We selected three optimal excipient mixtures to spray dry with BCG. Then the
viability of BCG in the optimized dry powders was evaluated in different storage
conditions. We also studied BCG stability in powders with protective packaging (presence
of desiccant and reactive oxygen scavengers). These studies will be completed after 18
months and are still ongoing; however, it appears that all three optimized powder
formulations offer improved temperature stability (after 2-4 weeks of storage) with or
without the packaging protection compared to leucine powder (Fig. 3.7).
Additionally, we assessed the three optimized BCG powders for aerosolization
properties. The powder morphology was observed by SEM, which showed them to be
rough, porous, and spherical (Fig. 3.4). The optimized powders were in the respirable size
range, with Dx (50) of 2.02-2.14μm (Table 3.2). Optimized powders also proved more
resistant to moisture uptake than the leucine powder. Together, these data suggest that we
have improved the overall characteristics of BCG dry powders, compared to the previously
published BCG-leucine dry powder, by adding excipients which improve powder size for
pulmonary delivery, limit moisture uptake, increase the amorphous nature, and improve
the thermostability of BCG.
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Materials & Methods
Factorial design of excipients
A factorial design of excipients was prepared using Design-Expert® Software (Stat-Ease,
Inc.; MN, USA). A mixture study design consisting of different proportions of five
excipients were used as the process variables (Table 3.1). Five responses variables were
evaluated including yield, size, residual moisture content after spray drying,
hygroscopicity, and glass transition temperature (Tg) of the spray-dried powders. The
factorial design was initially performed without incorporating the live BCG vaccine into
the powders in order to select the best excipient combination for long-term stability.
Solution preparation
Different proportions of five excipients were chosen based on previous literature using dry
powder for biologics. D-Mannitol (Sigma Aldrich, St. Louis, MO) was chosen for its low
hygroscopicity and a range of 0-20% w/w was used for the factorial design. L-Leucine
(Sigma Aldrich) was chosen for its flow properties and a range of 0-80% w/w was used.
Bovine Serum Albumin (BSA) (Fisher Scientific, Waltham, MA) was chosen for its protein
stabilizing utility and its ability to prevent recrystallization; a range of 0-5% w/w was used
for the factorial design. Trehalose (MP Biomedicals, Santa Ana, CA) and
polyvinylpyrrolidone (PVP) (Acros Organics, Geel, Belgium) were chosen for their high
glass transition temperatures and a range of 0-5% w/w was used for both excipients.
Excipients mixtures were added to distilled water to create a 1% (w/v) solution.
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Table 3.4 Properties of excipients used for spray-drying live BCG vaccine.

Excipients

Properties

Range

Leucine, L

Increases dispersibility of the dry 70-90%
powder

Mannitol, M Low hygroscopy

10-20%

Ref
239,281,284

285–287

Trehalose, T

Dessico-protectant; High glass transition 0-5%
temperature

233,234,236,239,281,288–

PVP

High glass transition temperature

0-5%

235,237,295

BSA

Prevents recrystallization

0-5%

237,296,297

294

Culturing BCG
Mycobacterium bovis BCG Pasteur (ATCC 35734) was grown in Middlebrook 7H9 broth
(Fluka analytical, Buchs, Switzerland) supplemented with 0.05% glycerol (Fisher
Scientific, Waltham, MA) and 10% albumin-dextrose-catalase (BD diagnostic Systems,
Franklin Lakes, NJ) at 37°C to mid-log phase of growth. In preparation for spray drying
BCG was pelleted at 1800xg and resuspended in the spray drying solution at approximately
108 CFU/ mL.
Spray drying
Blank Dry powders - were prepared by spray drying using a mini-spray dryer B-290 (Büchi
Corporation, Flawil, Switzerland) with a standard two-way nozzle (0.7mm diameter).
Spray drying parameters were the same for all factorial design powders and were as
follows: Inlet temperature 150 ± 5 ºC, outlet temperature 50 ± 5 ºC, aspirator rate 100%,
pump flow rate 10% (corresponding to 4 mL/min), and air flow rate 742 L/hr.
BCG Dry powder- Three excipient combinations were selected (Table 3.2) from the above
factorial design and spray-dried with BCG using the Büchi Mini Spray Dryer. Spray-drying
with BCG (BSL-2 agent) was conducted according to protocols reviewed and approved by
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the Institutional Biosafety Committee (IBC) at the University of New Mexico. The same
spray drying parameters used for the blank powders were used again for BCG. A 0.2 µm
EMFLON Filter (Pall Life Sciences, Port Washington, NY) was attached in-line to the
exhaust of the spray-dryer immediately after the PTFE membrane filter to prevent release
of BCG to the atmosphere. In addition, the spray-dryer was housed in a BioPROtect III
Jr® Bio Safety Cabinet (BSC, Baker Co., Sanford, ME; BSL-2 contained) to provide
protection to the dry powder vaccine from contamination and the operator from exposure
to BCG. All subsequent handling of the powders were performed in a BSC according to
the IBC approved protocol.
Dry powder characterization
Yield
Dry power yield was calculated by dividing the mass of powders collected after spray
drying by the mass of solid components added to feed solution.
100

% Yield =

Particle size and morphology
Particle size was measured using the Mastersizer 3000 (Malvern Instruments Ltd.,
Worcestershire, United Kingdom) and the dry powder dispersion system Aero S (Malvern
Instruments Ltd.). Particle size measurements were carried out at a feed rate of 4, sheer
pressure of 3bars. The average of three replicates was taken for each sample.
SEM
The surface morphology of the blank powders, blank leucine powder, and dead BCG
powder were characterized using S-5200 field-emission scanning electron microscope
(SEM; Hitachi, Schaumburg, IL). The powders were mounted on a double-sided carbon
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tape on an aluminum boat for visualization. The particles were then examined with a
resolution of 2nm at low voltages (2kV) and currents to prevent the collapse of the powders.
TEM
The BCG mycobacteria were visualized after spray drying using a 200CX transmission
electron microscopy (TEM; JEOL, Peabody, MA) operated at 200kV. Powders were
dispersed and fixed in 10% w/v paraformaldehyde (Sigma Aldrich) prior to imaging. The
suspension was negatively stained with phosphotungstic acid (PTA) and visualized under
different magnifications.
XRD
The crystallinity of the spray-dried formulations was assessed by X-ray diffraction. XRD
patterns were obtained for the optimized spray-dried formulations (powder 1, 2, 3, and
Leucine) using a RigaKu SmartLab X-ray diffractometer (Rigaku Corporation, Tokyo,
Japan). Samples were placed on a steel sample holder and subjected to compaction for a
leveled surface before analysis. The samples were then analyzed at room temperature in
the angle range of 2-150° 2θ with a step size of 0.02° and in continuous scan mode with a
scanning rate 6.2° min. The crystalline nature of the powders was assessed by examination
of the resulting diffraction patterns.
Moisture content
The moisture content of dry powders was assessed by placing a known mass of dry powder
in a drying oven at a temperature of 120 ºC for 48 hr. Weight loss after heating was recorded
as weight of water in the dry powder.
100

% H2O composition =

91

Hygroscopicity
The ability of the powders to take up water was measured by placing a known mass of each
powder in a humidified (>80%) incubator for 48 hrs. Weight gain was recorded as weight
of water absorbed.
% H2O uptake =

100

Glass transition temperature (Tg)
Glass transition temperature (Tg) was assessed using Differential Scanning Calorimetry
(DSC) and was carried out on a DSC Q 2000 (TA Instruments, Delaware, USA) with
refrigerated cooling system 90 (TA Instruments) and nitrogen gas purge. Scanning was
done in a heat, cool, heat method with rates of 5ºC/min to 170ºC, -20 ºC, and 170 ºC
respectively. Standard sample pans (TA Instruments) were used.
BCG loading
Dry powders containing BCG were assessed for viability and loading by plating on
Middlebrook 7H10 agar (Fluka analytical, Buchs, Switzerland) supplemented with 0.05%
glycerol (Fisher Scientific) and 10% oleic acid-albumin-dextrose-catalase broth for 14-21
days at 37oC.
Storage stability studies
Powders where kept at several environmental conditions including 4ºC, 25º, 37º and 40ºC
in scintillation vials with and without humidity. The powders were packaged two different
ways; in scintillation vials with a simple screw cap and a packing vial with contains a
desiccant and ROS scavenger insert (nitrogen purged and air tight seal) developed in our
laboratory previously298. The Table 3.5 shows conditions and the timeline shows plating
schedule.
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Table 3.5 Storage conditions for powders.
Packaging
Type

‐20°C

4°C

25°C

40°C
75RH

scintillation
vial

X

X

x

x

X

x

x

anaerobic
packaging

/

25°C
40RH

x

/

25°C
60RH

/

x
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Chapter 4.

SUMMARY AND DISCUSSION

Mtb is an age-old human pathogen which still causes significant illness and mortality.
Every year 9.6 million people contract the illness and 1.5 million die9. These statistics
support TB as one of the most deadly infectious diseases worldwide. Importantly, over
95% of TB deaths occur in the developing world. Treatment and care for individuals in
these areas is complicated by many factors including economic constraints, access to
medical care, high incidences of antibiotic resistant strains, and HIV co-infection. For these
reasons, the WHO has made research in TB vaccines, new drugs, and diagnostics a priority
of the Stop TB Strategy299.
Currently, the only available vaccine against Mtb is BCG, which is minimally
effective in terms of protection130,145. While there are many possible explanations for
failures of BCG, growing evidence suggests that EM may be interfering with the protective
efficacy of the vaccine136–140. EM are found in soil, water, and air sources in areas of the
world where BCG is not protective and TB is rampant128,135. No clear mechanism of EM
interference has been elucidated, although several hypotheses have been proposed and
continue to be debated136,140,247. Additionally, a promising vaccine candidate recently failed
to be more protective than BCG in field trials, possibly due to interference by EM165.
The research described herein significantly advances the field of TB vaccines. In
Chapter 2, we describe our work to elucidate the mechanism behind EM interference with
BCG protection. We demonstrate a tolerogenic immune phenotype linked to chronic oral
exposure of mice to EM. Chronic dermal exposure to EM did not generate this tolerance,
suggesting that the GI tract plays a critical role in this interference mechanism (oral
tolerance). We further showed that EM-tolerant mice did not respond to intradermal BCG
vaccination (the current route of human BCG immunization), suggesting that oral tolerance
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to EM manifests itself systemically. Lastly, we demonstrated that pulmonary BCG
vaccination was able generate a Th1 immune response in the airway of EM-exposed mice
and provided protection against a subsequent Mtb challenge.
In Chapter 3, we describe our work to formulate a stable dry powder BCG vaccine
suitable for pulmonary administration. This work builds upon previous research which
described BCG dry powders formulated with L-leucine as an excipient. Here, we show a
more stable BCG dry powder formulation using a factorial design of excipients to create a
dry powder that can be stored for long periods at a wide range of temperature and humidity
conditions.
In this concluding chapter, Chapter 4, we will address some of the criticisms of
the designs and methods used. Next, we will propose research to address these gaps, and
finally, we will discuss the clinical implications of this work.

Suitability of pulmonary immunization in EM exposed hosts
Although the research herein makes advances in the field of TB, there are a few limitations;
(1) The EM-exposure mouse model, (2) Mouse model in the study of TB vaccines, (3)
Accelerated storage conditions to evaluate long-term powder stability, and (4) Evaluating
dry powder vaccines in vivo.
The fundamental hypothesis of this work is that pulmonary BCG immunization
would be protective in EM-exposed populations, where intradermal BCG is known to be
poorly protective. In developing an EM-exposure mouse model we discovered that chronic
oral exposure to EM was critical in generating tolerance to systemic BCG vaccination
(Chapter 2, Fig. 2.2). However, chronic intradermal exposure to EM did not generate
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tolerogenic phenotypes. This study supports previous clinical findings that patients
presenting with EM infections have elevated T regulatory cell counts, as well increased
serum levels of IL-10 and TGF-β264. Furthermore, these patients do not respond to
mycobacterial antigens264. Patients orally tolerized to bacteria also shed bacteria in their
feces as their GI tract is colonized300,301.
However, to show that EM tolerance is fundamentally related to the oral route of
exposure only, we must rule out aerosol exposure. EM are present in the air and may be
inhaled as aerosolized droplets18,19. While this does not appear to be the primary route of
exposure19, future studies should take this into consideration. It is challenging to administer
chronic EM exposure by the pulmonary route without delivering some EM into the GI tract
(via mucociliary clearance). We initially attempted to expose mice to pulmonary EM using
the same method of intubation that we had used for pulmonary BCG immunization.
However, these mice seemed to lose weight from chronic intubation and isofluorane
exposure.
An additional question related to EM exposure is derived from the timing of the
exposures in relation to vaccination. Previous studies exposed mice to EM before BCG
vaccination136,138, an exposure model which we adopted for our studies. However, it is
much more likely that EM exposure takes place both before and after BCG vaccination. In
the majority of countries which include BCG in their vaccination program, BCG is given
in the first three years of life. BCG vaccination is known to be effective in children, but
immunity wanes into adulthood302. Thus, it may be that chronic EM exposure has the
greatest effect after BCG vaccination, in which case EM exposure regimens would need to
reflect this.
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Another major limitation is the mouse model we used for our in vivo studies. Mouse
models are the current animal of choice to study the immune response to TB303. However,
the mouse model does not accurately reflect human TB lung pathology, as mice are
resistant to Mtb infection. In addition, mouse infection timelines with regards to disease
pathology do not correlate to human disease progression timelines. The studies described
in Chapter 2 were designed to assess short-term protection against Mtb, a commonly used
endpoint136,138,140. Conversely, it may be necessary to assess the long term protection of
pulmonary immunization, which has been done less often in the literature and is widely
varied in terms of endpoint.
Another limitation of this research is the lack of a relevant accelerated storage
system to evaluate our optimized BCG dry powders. Currently, there are no guidelines in
the literature for temperature and storage timelines. For this reason, in Chapter 3 we
include a large range of temperature and humidity conditions. However, these studies need
to incorporate all of the solutions (in addition to the dry powders) at each storage condition
to truly assess whether our dry powders are superior in terms of stability.
Lastly, the ultimate assessment of BCG dry powder should include long-term
stability data and antigenicity studies, which were not addressed in Chapter 3. Long-term
stability studies at a multitude of environmental conditions will be required to robustly
evaluate the dry powder BCG longevity. It will also be important to address whether there
is any loss in the antigenicity of BCG, especially after the spray drying process.
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Alternative strategies to investigating EM exposure and pulmonary BCG
vaccination
There are many limitations associated with using a mouse model of tolerance and
tuberculosis. Perhaps the most important in terms of tolerance is related to our exposure
model of EM. To address pulmonary EM exposure, it may be necessary to create an
inhalation chamber, where mice would be exposed to aerosolized EM without constant
trauma to the trachea. There are commercial versions of such single animal chambers,
called Glas-Col® chambers, which could be employed; alternatively, a chamber could be
fabricated for group exposure inside a biosafety cabinet.
Additionally, more exposure timelines need to be assessed to fully understand EM
interference. Specifically, a model which exposes mice to EM after BCG vaccination must
be assessed. This animal model could expose mice a few times prior to BCG and many
times after in order to properly mimic human exposure. It may also be useful to change
exposure frequency and dosing to understand if there is a threshold associated with the
tolerance that we observed.
To address the limitations of the mouse model, we can use the Kramnik mouse
model for studies looking at pathology. The model is named after Igor Kramnik who first
described the C3HeB/FeJ mouse strain. These mice contain a recessive allele which makes
them highly susceptible to Mtb infection304. Differences in the super-susceptibility to
tuberculosis-1 (sst1) on chromosome 1 and the intracellular pathogen resistance 1 (Ipr1)
isoform of the interferon-inducible-75 (Ifi75) gene are responsible for the decreased
control over bacterial replication and the formation of caseous necrotic granulomas in
Kramnik mice304. Furthermore, the structure of the granulomatous lesions are similar to
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humans and these mice have shown to better mimic human TB progression304. It is
important to note that aside from increased susceptibility to TB infection Kramnik mice
have a fully intact and functional immune system304. While the limitations of this model
are still being explored, one study reported that the first-line TB antibiotic PZA (see
Treatment of Mtb) had no bactericidal effects in the Kramnik mouse, suggesting that it
may not be a good model for evaluating all anti-TB drugs304. Alternatively, a guinea pig
model of tuberculosis could be utilized. It is a well characterized animal model of TB
infection, specifically in the study of TB antibiotics and host pathology. To this end, guinea
pigs develop severe TB disease and Kaplan-Meier survival curves can be used in these
animals to further assesses BCG protection.
Future experiments should also examine tissue resident memory T cells in the
airway. These T cells are non-circulating and reside primarily in the peripheral tissue305.
These cells can elicit rapid and robust in situ protective responses251,305. Importantly, some
studies have suggested that these cells have a greater likelihood of providing long-term
immunity306. This would be critical in the case of any TB vaccine, as immunity against TB
wanes during adulthood. These cells can be isolated using the markers CD69 and CD103
during flow cytometry studies for future work to assess whether pulmonary BCG generates
more tissue-resident immunity than intradermal BCG.
Finally, it will be useful to re-examine the heterologous prime boost vaccination
strategy in conjunction with our pulmonary BCG immunization model. Boosting has
shown little success in intradermal TB vaccination studies307. However it would be
interesting to test a pulmonary boosting of a TB vaccine after pulmonary BCG delivery.
Our results in Chapter 2 suggest that boosting may have failed due to tolerance against
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mycobacteria. It may be that a pulmonary boost increases long-lived immunity in the
airway, while intradermal vaccination and boosting could not.

Future studies to optimize a dry powder BCG
The long-term stability of dry powder BCG is still ongoing, and there are a questions left
to be answered. While the factorial design of excipients resulted in three optimal excipient
formulations, there are still many experiments that must be done to validate their longevity.
First and foremost, the spray drying of each of the powders must be repeated to confirm
the powder characteristics associated with each formulation. This will reveal batch-tobatch differences resulting from the spray drying process. All characterization
methodologies will be recapitulated. Ideally, we would also add two additional
characterizations, thermogravimetric analysis (TGA) and next generation impaction (NGI).
TGA would allow us to analyze residual moisture in a more accurate manner. Currently,
we are employing gravimetric analysis by weighing powders manually before and after the
drying step, which adds an element of error to each measurement. The second method that
we would like to employ is the use of the NGI to measure the mass median aerodynamic
diameter (MMAD), fine particle fraction (FPF), gravimetric standard deviation (GSD), and
total emitted dose (TED). These values are important for any powder designed for
pulmonary administration. MMAD, along with GSD, measure the distribution of mass of
an airborne dry powder as they compare to the aerodynamic diameter. The FPF determines
the respirable particles based on their aerodynamic size and TED describes how much of a
dose is emitted out of a dry powder inhaler (DPI). Together, these values describe how a
dry powder will disperse in the lungs of humans.
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Stability studies to assess the longevity and stability of these dry powder vaccines
must be completed. The data shown herein (Chapter 3; Fig 3.5&3.6) represent only the
first two weeks of data for the unprotected samples and one month for the protected
samples. Studies must assess long-term stability at multiple temperature and humidity
conditions to truly predict their stability. In addition, solution controls must be added to
each storage condition for comparison to its associated dry powder. Based on current data,
we expect that the unprotected dry powders will lose viability at an accelerated rate in the
40ºC/75% RH storage environment. However, previous work from our laboratory has
shown that with protection via packaging, viability losses can be minimized in this extreme
environment298.
The last goal of this work will be to attempt in vivo characterization. This goal
would be broken into multiple parts. First, we would view dispersion of the powders in an
ex vivo mouse lung model. Powders would be spray-dried with a florescent dye to visualize
the powder placement in the lung. This will assess the ability of the dry powder to flow
into the deep lung with use of the Penn Century Dry Powder Insufflator™ (PCI). The PCI
is similar to the microsprayer used in Chapter 2; it deposits its payload into the lung via
an endotracheal tube inserted to the depth of the lung carina. This device has many flaws,
but it is the only one of its kind on the market. The primary issue of the device is its
tendency to clog with powders as they take up moisture in the humid lung environment,
making it difficult to dose the animals. The ex vivo lung model should help predict how
well the insufflator and dry powder will work in vivo, which would be the next natural step
in the project. Using the mouse models described in Chapter 2, we would assess the
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powder’s ability to generate the appropriate Th1 response and protect against Mtb
infection.

Clinical implications of pulmonary BCG vaccination
Current TB vaccination strategies, intradermal BCG and pre-clinical candidate vaccines,
have been largely unsuccessful. TB remains one of the deadliest infectious diseases to date
despite being thousands of years old. EM may be a significant factor in the failure of BCG.
Initial investigations into the failures showed that BCG failure correlated directly with
areas of high EM exposure128,135. Additionally, it has been shown that EM inhibits effective
BCG immunization in animal models of TB136,138–140,263. Promising vaccine candidates
continue to fail when assessed in randomize field trials where EM exposure may be a
factor188,203.
The research described here suggests that the failure of BCG and other vaccine
candidates does not lie in the antigen component of the vaccine, but rather in the delivery
route. We have shown evidence which proposes that EM exposure by the oral route
tolerizes mice systemically to mycobacteria. Vaccines which use mycobacterial antigens
to generate adaptive immunity against Mtb will be subject to this tolerance, rendering them
ineffective.
In a broader sense, these studies suggest that there may be a relationship between
the immune response generated to the microbiome of the GI tract and how individuals
respond to vaccines. The microbiome does not become stable and mature in humans until
two years of age308. Infants two years or younger have variable microbiota composition
and are susceptible to alterations driven by environmental exposures308,309. These changes
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in microbiota composition can have long-term effects on the host immune system308,310.
One of the three major environmental impactors of early microbiota community is hygiene
(food and water sanitation), the other two being diet (breast-fed or formula fed) and
delivery method (vaginal or caesarean birth)308,311. This is supported by research showing
that in areas of the world with poor hygiene there is decreased oral vaccine efficacy308,
specifically to the oral cholera vaccine312,313, rotavirus vaccine314–316, and polio vaccine317.
Therefore, future vaccine research must take environmental exposures into account,
specifically those which effect the GI microbiota.
Additionally, we have shown that BCG administered by the pulmonary route is not
subject to EM-generated oral tolerance. Immunosuppressive cells generated in the GI tract
translocate systemically but do not reach the airway. In this way, a BCG-specific Th1
immune response is generated in the airway, despite a systemic Th2/Treg response.
Importantly, this immunity was found to be protective in EM-exposed mice challenged
with Mtb.
This has vast implications in the field of TB. Most importantly, it means that we
may be vaccinating patients by the wrong delivery route. However, there are currently very
few pulmonary vaccines on the market. MVA85A, a TB vaccine which failed in initial
field trials when given by the intradermal route165, is now in clinical trials as a pulmonary
vaccine203. Based on the work described here, we predict that it will be more protective.
It is also important to note that other vaccines have proven to be more effective when
delivered by the pulmonary route. For example, the FluMist® quadravalent vaccine which
is administered intranasally to immunize against the flu. The flu is a common respiratory
disease caused by the influenza virus. There are two vaccines currently available against
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influenza, the aforementioned FluMist® and its predecessor which is an injectable vaccine
(flu shot). The vaccines not only differ in administration route, but also contain different
antigens. FluMist® contains live attenuated virus whereas the flu shot contains inactivated
(killed) virus. Importantly, a meta-analysis of a different comparison studies of the two
vaccines reported that FluMist® was more effective at preventing illness caused by the
seasonal influenza virus (82% of illness prevented versus 59% with the shot)318. This
corroborates with the research described herein, and that of others123,319,320, which shows
that pulmonary route of vaccine administration may be more effective against respiratory
diseases.
Lastly, this work comments on vaccine design in terms of formulation. The WHO
reports that 1.5 million children die from vaccine-preventable diseases annually271,277,
prompting the question - why? Certainly there are economic concerns, especially in
resource-poor countries. However, the WHO and other vaccination agencies, also report
that 20-50% of vaccines are exposed to hot or freezing temperatures which may decrease
their potency269,272,277,321. This means that we may be vaccinating children with ineffective
vaccines.
Dry powder vaccines offer solutions to both of these problems. Nearly 80% of the
cost of vaccines comes from costs associated with cold-chain storage226. We show here that
dry powder vaccines can be designed and formulated to withstand the harshest
temperatures and environments. This potentially decreases costs associated with cold
chain, and ensures that vaccines are not damaged before they are given. We have
formulated which is designed to give BCG, a live vaccine, longevity and stability during
storage. The methods, excipients, and packaging described in this work can help direct the
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design of future vaccines against a multitude of infectious diseases to ensure that these
vaccines are safe, affordable, and most importantly, effective.
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Appendix A: Abbreviations
APC – Antigen presenting cell
AERAS-402 rAd – Recombinant adenovirus construct expressing Ag85A and TB 10.4
BALF – Bronchioalveolar lavage fluid
BCG – Bacille Calmette-Géurin
BSA – Bovine serum albumin
DPI – Dry powder inhaler
DSC – Differential scanning calorimetry
DTH – Delayed-type hypersensitivity
EM – Environmental mycobacteria
EMA - European Medicines Agency
EMB - Ethambutol
EPI – Expanded Program on Immunization
FDA- Food and Drug Administration
FPF – Fine particle fraction
GI tract – Gastrointestinal tract
GSD – Geometric standard deviation
ID – Intradermal
Ifi75 - Interferon-inducible-75
IFN-γ – Interferon gamma
IGRA - Interferon gamma release assay
IL-2 – Interleukin 2
IL-10 – Interleukin 10
IL-17 – Interleukin 17
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Ipr1 - intracellular pathogen resistance 1
INH - Isoniazid
MDR – Multi-drug resistant
MMAD – Mass median aerodynamic diameter
Mtb – Mycobacterium tuberculosis
MVA85A - Modified Vaccinia Ankara (MVA) construct expressing antigen Ag85A
NHP- Non-human primates
NP BCG – No packaging protection BCG
O-MA – Oral M. avium
P BCG – Packaging protected BCG
PCI - Penn Century Dry Powder Insufflator™
PD-1 - Programmed cell death protein 1
PDL-1 - Programmed cell death ligand 1
PDL-2 - Programmed cell death ligand 2
PPD – Purified protein derivative
PUL - Pulmonary
PVP – Polyvinylpyrrolidone
PZA – Pyrazinamide
RIF – Rifampicin
RH – Relative humidity
RD1 – Region of difference
SEM – Scanning electron microscopy
Sst1 - Super-susceptibility to tuberculosis-1
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TB – Tuberculosis
TDR – Totally drug resistant
TED – Total emitted dose
TEM – Transmission electron microscopy
TLR – Toll-like receptor
TRM – Tissue-resident memory T cells
Tg – Glass transition temperature
Th1 – T helper cell type 1
Th2 – T helper cell type 2
Th17 – T helper cell type 17
TGA – Thermogravimetric analysis
TGF-β – Tumor growth factor beta
TNF-α – Tumor necrosis factor alpha
Treg – T regulatory cell
WHO – World Health Organization
XDR – Extensively drug resistant
XRD – X-ray powder diffraction
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Appendix C: Figures

Figure 1.1 The race between antibiotic development and evolution of Mtb drug resistance. Antibiotic development against Mtb has slowed over
the past 50 years. Concurrently, Mtb drug resistance strains have emerged, limiting treatment options for patients.
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Figure 1.2 The global efficacy of BCG. The efficacy of BCG at protecting against Mtb varies geographically. Countries shown in orange have effective
immunization programs as measured by number of Mtb infections. Countries shown in red have ineffective immunization programs. Countries shown in
tan do not vaccinate against Mtb.
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Figure 1.3 Proposed mechanisms for BCG failure due to EM interference. A) Masking Hypothesis, and
B) Blocking Hypothesis. Y-axis depicts protective efficacy and x-axis depicts time exposed to the antigen.
Dashed line represents the arbitrary level of immunity. A) The masking hypothesis reasons that BCG
immunity required in an EM-exposed host never surpasses the immunity gained in response to EM-exposure
alone. B) The blocking hypothesis suggests that BCG is vulnerable to achieve protection against Mtb existing
mycobacterial immunity in an EM-exposed host and cannot remain long enough in the lungs to generate
BCG-specific immunity.
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Figure 1.4 Biomimickry: Using natural Mtb infection to inform vaccine design. Mtb infection naturally occurs by the pulmonary route. While BCG mimics
Mtb by sharing antigenic similarities, it is currently given by the intradermal route which does not mimic the natural infection route. Administering BCG by the
pulmonary route would more naturally emulate infection, and hopefully provide better long-term protection.
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Figure 1.5 The effect of immunization route on immunity in the airway. A) Intradermal immunization
generates T cells which migrate into the systemic circulation and lung parenchyma. However no immunity
in the airway is generated. B) Pulmonary and intranasal immunization generate T cells which migrate to the
systemic circulation, lung parenchyma, and the airway.
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Figure 1.6 The spray drying process. (A) The Buchi mini spray dryer-290, (B) A Schematic of the spray drying process. Images adopted from: Buchi229 and
Pelkonen322.
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Figure 2.1 Differences in cytokine response to BCG immunization were observed between mice that
were or were not presensitized to oral M. avium prior to intradermal BCG vaccination. (A)
Experimental design. Arrows indicate M. avium exposure. (B) Interferon-gamma (IFN-γ) secretion in
response to restimulation of splenic and lung T cells from mice exposed to either intradermal BCG or oral M.
avium with either heat-killed whole BCG or M. avium, n=6. (C) IFN-γ secretion in response to heat-killed
whole BCG antigen restimulation of splenic and lung T cells from different treatment groups, n=6. (D)
Interleukin-10 (IL-10) secretion in response to BCG restimulation of splenic and lung T cells from groups
intradermally immunized with BCG with and without oral M. avium presensitization, n=4. A Mann-Whitney
U test or multiple t-tests (Holm-Sidak) were used for comparison of two data sets, and a one-way ANOVA
Kruskal-Wallis with Dunn’s multiple comparison post-test for multiple data sets. *p<.05; **p<.01; data
shown with standard error of the mean (SEM).
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Figure 2.2 Analysis of cell phenotypes present in spleen and lung tissues after oral or intradermal
presensitization to M. avium. (A) Experimental design. Arrows indicate M. avium exposure. (B & C)
Number of CD4+, CD8+, CD11b+, and CD4+FoxP3+ cells in the spleens (B) and lungs (C) of mice; n=8
over two separate experiments. (D) Number of M. avium CFU in the feces of mice presensitized to M.
avium by different exposure routes. A Mann-Whitney U test was used for comparison.*p<.05; **p<.01;
***p<.001 data shown with standard error of the mean (SEM).
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Figure 2.3 Pulmonary versus intradermal BCG immunization. (A) Experimental design. Arrows indicate M. avium exposure, (B) Number of BCG CFU
in lungs of different immunization groups, n=6 over two separate experiments. Post immunization IFN-γ production by BCG-stimulated T cells in the (C)
spleen, (D) Lung, and (E) BALF, n=6. A one-way ANOVA Kruskal-Wallis with Dunn’s multiple comparison post-test was used to determine statistical
significance. *p<.05; **p<.01; data shown with standard error of the mean (SEM).
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Figure 2.4 Analysis of cellular correlates of protection in different immunization groups with and
without oral M. avium presensitization. (A) Experimental design. Arrows indicate M. avium exposure.
(B) CD4+ cells, (C) CD8+ cells, (D) CD44hiCD62lo memory cells, (E) CDllb+ (and CD11c+ for lung and
BALF) macrophages present in the spleen, lung, and BALF (airway) compartments, n=8 over 2 separate
experiments. A one-way ANOVA Kruskal-Wallis with Dunn’s multiple comparison post-test was used to
determine statistical significance. *p<.05; data shown with standard error of the mean (SEM).
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Figure 2.5 Mtb aerosol challenge studies. (A) Experimental design. Mice immunized with BCG by the intradermal and pulmonary route, with and without
presensitization with oral M. avium, were challenged with Mtb. (B) Number of BCG CFU in lungs of different immunization groups, n=4-15 per group. A oneway ANOVA Kruskal-Wallis with Dunn’s multiple comparison post-test was used to determine statistical significance. *p<.05; data shown with standard error
of the mean (SEM).
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Figure 2.6 Histopathological analysis of lung and spleen tissue after Mtb aerosol challenge in different immunization groups, with and without oral M.
avium presensitization. (A) H&E-stained lung sections were assessed for granulomatous inflammation, arrows indicate foci of granulomatous inflammation. (B)
Higher magnification (5X) of lung sections. (C) Spleens were assessed for lymphoid hyperplasia, the arrow indicates an area of white pulp used to assess lymphoid
hyperplasia. n=2 mice per group, data shown is from one experiment and representative of three independent experiments.
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Figure 2.7 Pulmonary BCG immunization is effective at protecting against Mtb in EM-exposed hosts chronic oral exposure to EM generates systemic
tolerance against mycobacteria. This tolerance generates poor immunity in a subsequent intradermal BCG vaccination scenario, and could lead to variable
vaccine efficacy. However, because systemic tolerance is not present in the airways of hosts, pulmonary immunization generates robust immunity and is
protective against Mtb challenge.
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Supplemental 2.1 M. avium CFUs in lung and spleen after different routes of presensitization. M.
avium in the lung and spleen of mice presensitized by either the oral or intradermal route, n=8.
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Supplemental 1.2 Animal weights after infection. Weight gain after infection; n=8. A one-way ANOVA
Kruskal-Wallis with Dunn’s multiple comparison post-test was used to determine statistical significance.
*p<.05; data shown with standard error of the mean (SEM).
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Figure 3.1 Effect of changing excipient ratios on powder physical properties. A) Yield, B) Size, C)
Residual moisture after spray drying, D) Moisture uptake, and E) Tg as shown by Piepel trace plot. For each
trace plot: A-Mannitol, B-Leucine, C-PVP, D-BSA, E-Trehalose; ANOVA statistical analysis with p values
shown.
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Figure 3.2 Overall interaction of excipients and responses. Blue responses are favorable and red
responses are unfavorable with respect to optimized input parameters. White responses show no effect.
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Figure 3.3 XRD crystallography graphs of optimized formulations. Powder 1 is displayed on bottom in blue, powder 2 is in the middle in green, and powder
3 is on the top in red. Increasing intensity counts on the y-axis show structure crystallinity.
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Figure 3.4 SEM and TEM visualizations of dry powder particles. (A&B) SEM at 10,000x magnification, A) powder with dead BCG, and B) powder
2; (C&D) TEM at 3000x magnification, C ) Mixture 2 with BCG, and D) Leucine with BCG.

146

Figure 3.5 BCG loss after spray drying. Gray portion of bar shows loss in BCG viability immediately after the spray drying process
compared to the pre-spray drying CFUs (whole bar).
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Figure 3.6 Stability of package protected dry powders. Viability of dry powder BCG stored in protected packaging at A) 4ºC, B) 25ºC at 40%
RH, C) 25ºC at 60% RH, and D) 40ºC.
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Figure 3.7 Stability of unprotected dry powders. Viability of dry powder BCG stored in without
protective packaging (A-D) at A) 4ºC, B) 25ºC at 40% RH, C) 25ºC at 60% RH, D) 40ºC/ 75RH; and E)
Solutions at 4 ºC.
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Appendix D: Tables
Table 1.1 Different species of Mycobacteria
M. tuberculosis complex:
M. tuberculosis*

M. bovis (bovis &

M. bovis BCG

M. microti*

M. africanum*

M. canetti

M. pinnipedii

M. nonchromogenicum*

caprae)

*

M. avium complex (MAC) other related species:
M. intracellulare*
M. lepremurium*
M. avium*

M. paratuberculosis*

Slow growing photochromogens:
M. kansasii*
M. asiaticum*

M. marinum*

M. simiae*

Slow growing scotochromogens :
M. gordonae*
M. scrofulaceum*

M. szulgai*

Slow growing non-chromogens
M. branderi
M. celatum

M. gastri*

M. haemophilum*

M. farcinogenes*

M. malmoense*

M. shimoidei

M. shinshuense

M. triviale*

M. terrae*

M. ulcerans*

M. xenopi*

Rapid growers:
M. aichense

M. agri

M. aurum*

M. austroafricanum

M. chelonae

M. chitae*

M. chubuense

M. diernhoferi

M. duvalii*

M. fallux

M. flavescens*

M. fortuitum

M. gadium*

M. gilvum*

M. komossense*

M. neoaurum*

M. obuense

M. parafortuitum*

M. phlei*

M. porcium

M. pulveris

M. rhodesiae

M. senegalense*

M. segmatis*

M. sphagni

M. thermoresistibile*

M. tokaiense

M. vaccae*

M. confluentis

M. interjectum

M. intermedium

Non- or poorly cultivatable species:
M. genavense
M. leprae*

*Included in the original approved list of species by Skerman et al. in 1980
This table was modified from a graph in Tuberculosis Bacteriology by C.H. Collins et al.
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M. sylvaticum

Table 1.2 Antibiotics for treatment of TB

Drug

Year of
Discovery

First Line Drugs
Isoniazid
1952
(INH)
Pyrazinamide
1954
(PZA)
Ethambutol
1961
(EMB)
1963
Rifampicin
(RIF)
Second Line Drugs
Streptomycin
1944

Molecular Target

Effect

Enoyl-acyl carrier protein reductase

Inhibition of mycolic acid
synthesis
Inhibition of translation;
acidification of the cytoplasm
Inhibition of arabinogalactan
biosynthesis
Inhibition of transcription

S1 component of the 30S ribosomal
subunit
Arabinosyl transferases
Beta subunit of RNA polymerase

Para-amino
salicylic acid
Cycloserine

1948

S12 and 16S rRNA components of
the 30S ribosomal subunit
Dihydropteroate synthase

1955

d-alanine racemase and ligase

Kanamycin
Ethionmide

1957
1961

30S ribosomal subunit
Enoyl-acer carrier protein reductase

Capreomycin

1963

Amikacin
Ofloxacin

1972
1980

Bedaquiline

1997

Delamanid

2006

Interbridge B2a between the 30S
and 50S ribosomal subunits
30S ribosomal subunit
DNA gyrase and DNA
topisomerase
C-subunit of the F0 complex of
ATP synthase
Methoxy mycolic and ketomycolic
acid
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Reported
Resistance

Ref

yes

12,88,89

yes

12,90,91

yes

12,88,92

yes

12,88,93

Inhibition of protein synthesis

yes

12,88,94

Inhibition of folate biosynthesis

yes

12,95,96

Inhibition of peptidoglycan
synthesis
Inhibition of protein synthesis
Inhibition of mycolic acid
biosynthesis
Inhibition of protein synthesis

yes

12,97–99

yes
yes

12,100,101

yes

12,101,103

Inhibition of protein synthesis
Inhibition of DNA supercoiling

yes
yes

12,101,103

Inhibition of ATP synthase

yes

106–110

Inhibition of mycolic acid
synthesis

yes

109,111–113

12,88,102

12,88,104,105

Table 1.3 Different vaccines against TB in pre-clinical trials
Vaccine type

Antigens

Adjuvant

Formulation

Route of
Administration

Animal
Model

BCG
BCG

None
None

Dry powders
Sodium alginate MPs

Pulmonary
Oral

Guinea pigs
Mice

BCG

None

Lipid formulation

Oral

Mice

Aeras 402/Crucell Ad35
Ag85A, Ag85B, TB10.4

None

Dry powders

Pulmonary

‐

Ref

Whole cell vaccines
Live
attenuated
bacteria

Viral‐vectored

123
126
206
207

208

MVA (modified vaccinia
virus)

None

Nanopatch microneedle

transdermal

‐

Ag85B‐MPT‐64‐Mtb8.4

Incomplete Freund’s
adjuvant

Chitosan MPs

S.C.

Mice

DNA (hsp65)

Trehalose dimycolate

PLGA MPs

I.M.

Ag85B
DNA (hsp65)
DNA (Ag85B+MPT64
+MPT83)
Ag85A
DNA Ag85B
Ag85A
DNA‐HLA‐A‐0201
DNA‐Rv1733c
Bacteriocins
Trehalose dibehanate
DNA (hsp65)
ESAT‐6
Ag85B‐ESAT6
RUTI (detoxified cellular
fragments of M. tb)

Trehalose dimycolate
Trehalose dimycolate
Dimethyl dioctyldecyl
ammonium bromide
CpG
None
CpG
None
None
None
CAF01
None
CAF01
CTA‐DD/ISCOMs

PGLA MPs
PLGA MPs

Pulmonary
I.M.

Guinea pigs,
Mice
Guinea pigs
Mice

PLGA MPs

I.M.

Mice

Poloxamer 407 NPs
Chitosan NPs
Pluronic stabilized NPs
Chitosan NPs
PLGA‐PEI NPs
Liposomes
Liposomes
Liposomes
Liposomes
Liposomes

Pulmonary
S.C.
Pulmonary
Pulmonary
Pulmonary
I.V.
S.C.
Intranasal, I.M.
S.C.
Intranasal

Mice
Mice
Mice
‐
Mice
Mice
Mice
Mice
Mice
Mice

Liposomes

S.C.

‐

Subunit vaccines

Gene or
based

Antigen

209

210

211
212
213

214
215
216
217
218
219
220
221
222
223
224

None
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Table 1.4 Advantages and disadvantages of lyophilization and spray drying of vaccine formulations

Technique

Advantages

Disadvantages

Lyophilization

- Established method in
vaccine field
- Aseptic processing
- Limited process losses

-

Spray drying

- Controllable product format
- Easy to scale up
(Continuous processing
method)
- Customizable for different
delivery routes
- No freezing
- Particle is encapsulated (i.e.
particle engineering)

Adapted from McAdams et al.225
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-

Limited product formats
Requires reconstitution
Freezing step
Difficult to scale up (batch
process)
Time consuming
Energy usage
requirements
Process losses
Not well-established in
vaccine field
Aseptic processing more
difficult
Lack of regulatory
precedent

Table 1.5 Effect of spray drying process parameters on dry powder characteristics

Adapted from Buchi Mini Spray Dryer B-290 Manual229
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Table 3.1 Optimal excipient mixtures

Number

Excipient Formulation

Desirability

Leucine

Mannitol

PVP

BSA

Trehalose

*1

75.2

10.0

5.0

4.8

5.0

0.902-0.976

*2

73.3

11.7

5.0

5.0

5.0

0.890-0.978

*3

71.0

14.0

5.0

5.0

5.0

0.867-0.980

4

68.9

17.6

4.2

4.2

5.0

0.793-0.885

5

65.4

19.8

4.9

4.8

5.0

0.779-0.886

6

75.0

14.0

3.0

3.0

5.0

0.756-0.829

7

78.0

12.0

1.0

4.0

5.0

0.728-0.815

8

75.5

14.2

2.6

2.7

5.0

0.719-0.787

9

76.1

14.4

2.2

2.2

5.0

0.665-0.727

* Chosen excipient mixtures
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Table 3.2 Yields and sizes of optimized formulations

Formulation

Yield

Dx (10)

Dx (50)

Dx (90)

Tg

Powder 1

58.41

0.84 ± 0.00

2.06 ± 0.01

4.71 ± 0.06

38.41

Powder 2

58.48

0.85 ± 0.01

2.14 ± 0.01

4.93 ± 0.02

34.99

Powder 3

55.37

0.75 ± 0.00

2.02 ± 0.00

4.98 ± 0.05

32.01

Leucine

60.99

1.90 ± 0.01

5.29 ± 0.04

10.30 ± 0.10

--

53.35

0.99 ± 0.01

2.14 ± 0.06

4.66 ± 0.19

--

powder
Dead BCG
powder
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Table 3.3 Residual moisture and moisture uptake.

Formulation

% Residual Moisture

% Moisture Uptake

Powder 1

25

70

Powder 2

29

75

Powder 3

53

86

Leucine powder

49

103
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Table 3.4 Properties of excipients used for spray-drying live BCG vaccine.

Excipients

Properties

Range

Leucine, L

Increases dispersibility of the dry 70-90%
powder

Mannitol, M Low hygroscopy

10-20%

Ref
239,281,284

285–287

Trehalose, T

Dessico-protectant; High glass transition 0-5%
temperature

233,234,236,239,281,288–

PVP

High glass transition temperature

0-5%

235,237,295

BSA

Prevents recrystallization

0-5%

237,296,297
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Table 3.5 Storage conditions for powders.
Packaging
Type

‐20°C

4°C

25°C

40°C
75RH

scintillation
vial

X

X

x

x

X

x

x

anaerobic
packaging
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/

25°C
40RH

x

/

25°C
60RH

x

/

